Characterisation and validation of drug transport and GLP-1R function in primary porcine proximal tubular cells by Schlatter, Philipp
 
Characterisation and validation of  
drug transport and GLP-1R function  
in primary porcine proximal tubular cells 
 
 
 
 
 
Inauguraldissertation  
 
 
 
zur 
Erlangung der Würde eines Doktors der Philosophie 
vorgelegt der 
Philosophisch-Naturwissenschaftlichen Fakultät 
der Universität Basel 
 
von 
 
 
Philipp Schlatter 
 
aus Basel Stadt, Schweiz 
 
 
 
Basel, 2006 
 
- 2 - 
 
 
 
Genehmigt von der Philosopisch-Naturwissenschaftlichen Fakultät auf Antrag von 
 
Prof. Jürgen Drewe 
Prof. Jörg Huwyler 
 
 
 
Basel, den 24.10.2006 
 
 
 
          Prof. Dr. H.-P. Hauri 
Dekan 
 
 
 
 
- 3 - 
Acknowledgements 
 
Danksagung  
 
Als erstes möchte ich mich bei meiner Frau und unseren Kindern bedanken, die mich 
während der Dissertation unterstützt und mit mir Freude und Frust geteilt haben. 
Meine älteste Tochter hat immer wieder nach dem Wohlbefinden der Nierenzellchen 
gefragt (manchmal war es keine gute Frage).  
 
Die drei Jahre im Labor 411 sind im wahrsten Sinn des Wortes wie im Fluge 
vergangen. Zumindest habe ich es so empfunden. Dies habe ich vor allem der 
wirklich sehr guten Betreuung durch Jürgen und Heike zu verdanken. Den üblichen 
Problemen und Schwierigkeiten des Experimentierens, ohne die das Leben 
langweilig wäre, konnten sie mit vielen Ideen und Lösungen entgegenhalten.  
 
Dank der guten Arbeitsatmosphäre war die Motivation selbst durch unvollständig 
(oder gar nicht?) funktionierende Experimente nicht totzukriegen. In ganz schlimmen 
Fällen waren es auch hier Jürgen und Heike, die aufbauten und einem wieder 
Hoffnung gaben. Vielen Dank! 
 
Erstaunt und beeindruckt war und bin ich heute noch, dass Jürgen trotz seiner vielen 
Termine immer Zeit für uns findet und für die Schwierigkeiten Verständnis und 
Lösungen zeigte. Das ist nicht selbstverständlich, und ich weiss es sehr zu schätzen. 
Vielen Dank, Jürgen! 
 
Uschi, ein Juwel, hatte für das Funktionieren des Labors gesorgt, damit der 
Materialschlacht die Munition (Pipetten, Platten, …) nicht ausging.  
Ich vermisse jetzt schon unsere gemeinsamen morgendlichen, von klassischer Musik 
begleiteten Nierenisolationen (16 Mal!).  
 
Manisha hat diesbezüglich mit einem Alternativprogramm aufgewartet: Es gab 
Hirnisolationen. So manch einer wurde am Morgen etwas bleicher. Aber ich konnte 
durch ihr Projekt mit primären Zellen profitieren, da die Probleme oft ähnlicher Natur 
waren.  
- 4 - 
 
Christian war mit seiner mehrjährigen Erfahrung in Taqman und RT eine wunderbare 
Unterstützung, die ich oft in Anspruch nehmen konnte.  
 
Marco hatte durch sein Beispiel gezeigt, wie man Effizienz und Schnelligkeit vereint, 
so wurde es nie zu ruhig im Labor.  
 
Angelika und Birk, die “Neuen” im Bunde, haben das Labor vor dem Aussterben 
bewahrt und durch ihre frischen Ideen belebt. 
 
Danken möchte ich auch den 410er für die gute Zeit, die wir verbringen konnten: 
Andrea, Anja, Bettina, Katri (durch sie konnte ich meine Finnischkennnisse auf dem 
laufenden halten), Katarina, Michael, Priska und Saskia. Liliane und Markus waren 
bei der Betreuung der Diplomarbeit von Dorina Saurer eine grosse Hilfe, wenn es um 
HPLC ging.  
 
Auch wenn TDM und Klips-Anfragen manchmal den Experimentierfluss 
unterbrachen, war es eine tolle Erfahrung. Hier möchte ich mich vor allem bei 
Alexandra für die Mühe und Geduld bedanken.  
 
Vielen Dank auch an Jörg Huwyler für die Übernahme des Korreferates und Prof. 
Hamburger für den Prüfungsvorssitz meiner Dissertationsprüfung.  
 
Unsere Wege trennen sich. Dieser Moment war abzusehen, doch er kam schneller 
als gedacht. Ich hoffe, dass wir auf die eine oder andere Weise noch Kontakt haben 
werden. Das Labor 411 wird mir in bester Erinnerung bleiben, vielen vielen Dank für 
alles.  
 
 
 
 
 
 
 
 
 
- 5 - 
Abbreviations 
 
 
ABC   ATP binding cassette 
ACE   angiotensin concerting enzyme 
AST-120  oral charcoal adsorbent 
ATP   adenosine-5’-triphosphate 
AUC   area under the plasma concentration-time curve 
AZT   azidothymidine alias zidovudine  
BCRP   breast cancer resistance protein 
BMDP  brain multidrug resistance protein  
cAMP   cyclic adenosine monophosphate  
cGMP   cyclic guanosine monophosphate 
CHP    calcineurin B homologous protein 
CT   threshold cycle 
DOTATOC somatostatin analogue: [1,4,7,10-tetraazacyclododecane-
N,N′N′′,N‴-tetraacetic-acid-D-Phe1-Tyr3 ]-octreotide  
DPPIV  dipeptidylpeptidase IV 
FITC   fluorescence marker 
FTC   fumitremorgin C 
P-gp   P-glycoprotein alias MDR1 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
GLP-1R  glucagon like peptide receptor 
GLUT   facilitative sodium independent sugar transporter 
HEK   human embryonic kidney 
HIV   human immunodeficiency virus 
HK2   immortalised human proximal tubular cells 
HKC   human kidney epithelial cell line 
kDa   kilo Dalton 
KM   Michaelis constant 
LLC-PK1  immortalised porcine proximal tubule cell line 
MDCK  Madin-Darby canine kidney 
MDR   multi-drug resistance 
MK571  cysteinyl leukotriene 1 receptor antagonist 
- 6 - 
mRNA  messenger ribonucleic acid 
MRP   multi-drug resistance associated protein 
MTX   methotrexate 
NBC   Na+ / HCO3- cotransporter 
NBF   nucleotide-binding fold/domain 
NHE   Na+/H+ exchanger 
NSAID  non-steroidal anti-inflammatory drugs 
OAT   organic anion transporter 
OATP   organic anion transporting polypeptide 
OCT   organic cation transporter 
PAH   para-aminohippuric acid  
Papp   apparent permeability coefficient 
PDZ post synaptic density protein, Drosophila disc large tumour 
suppressor and zo-1 protein 
PEPT   peptide transporter 
PhIP 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, a dietary 
carcinogen 
PHT    peptide and histidine transporter 
PPPTC  primary porcine proximal tubular cell 
RT-PCR  reverse transcription polymerase chain reaction 
SGLT   sodium-dependent glucose cotransporter  
SLC   solute carrier 
SNP   single nucleotide polymorphism 
T3   triiodothyronine 
TEER   transepithelial electrical resistance  
TM   transmembrane domain 
 
 
 
 
 
 
 
 
- 7 - 
Table of contents  
 
 
Acknowledgements         3 
Abbreviations          5 
Table of contents          7 
Summary           10 
Aim of the thesis          13 
 
 
1. Introduction          15 
1.1. Kidney – an overview        15 
1.2. Transporters         16 
1.2.1. ABCB1 (MDR 1) and members of ABCB   18 
1.2.2. ABCC1-6 (MRP 1-6) and members of ABCC   19 
1.2.3. ABCG2 (BCRP) and members of ABCG   21 
1.2.4. SLC4A4 (NBC1)       22 
1.2.5. SLC5A1/2 (SGLT1/2)      23 
1.2.6. SLC9A3 (NHE3)       24 
1.2.7. SLC15A1/2 (PEPT1/2)      25 
1.2.8. SLC21A (OATP)       27 
1.2.9.   Overwiew of the SLC22A family     28 
1.2.9.1. SLC22A1-3 (OCT 1-3)      28 
1.2.9.2. SLC22A6-8, 11, 10  (OAT 1-5)     29 
1.3. Proximal tubular cells – which species?     31 
 
2. Primary porcine proximal tubular cells as a model for transepithelial  
drug transport in human kidney       32 
2.1. Abstract          33 
2.2. Introduction         33 
2.3. Materials          36 
2.4. Functional characterisation of transporters     36 
2.4.1. Cell Culture        36 
2.4.2. Transepithelial electrical resistance (TEER) measurement 37 
2.4.3. Functional assays       38 
- 8 - 
2.4.4. PCR         39 
2.4.5. Sequencing of slc15a1 (PEPT1) and slc22a8 (OAT3) PCR  
 Products        40 
2.4.6. Confocal microscopy      40 
2.4.7. Statistical analysis       41 
2.5. Results          41 
2.5.1. Expression of transporters at mRNA level   41 
2.5.2.  Sequencing        42 
2.5.3.  Functional assay       43 
2.5.4.  Uptake of fluorescein in viable cells    45 
2.5.5.  Immunostaining       45 
2.6. Discussion          47 
2.6.1. Expression of transporters on mRNA level   47 
2.6.2. Protein expression       48 
2.6.3. Tightness        48 
2.6.4. ABCB1 (P-gp)       49 
2.6.5. ABCC1-6 (MRP1-6)      50 
2.6.6. Slc22a6/8 (OAT1/3)      50 
2.6.7. Slc15a1/2 (PEPT1/2)      51 
2.6.8. Slc5a1/2 (SGLT1/2)      51 
2.6.9. Transporters in other cell lines     52 
2.6.10. Final conclusion       52 
 
3. Functional expression of BMDP in kidney     54 
3.1. Abstract          55 
3.2. Introduction         55 
3.3. Methods          57 
3.3.1. Materials        57 
3.3.2. Cell Culture        57 
3.3.3. RT-PCR for BMDP standards     57 
3.3.4. Real-time Polymerase Chain Reaction (TaqMan® Assay) 58 
3.3.5. Sequencing of GAPDH and BMDP PCR products  59 
3.3.6. Confocal microscopy      59 
3.3.7. Western blot analysis      60 
- 9 - 
3.3.8. Functional assays       61 
3.3.9. Statistical analysis       61 
3.4. Results          61 
3.5. Discussion          64 
 
4. Glucagon-like 1 receptor expression in primary porcine  
proximal tubular cells        69 
4.1. Abstract          70 
4.2. Introduction         71 
4.3. Materials and Methods        72 
4.3.1. Materials        72 
4.3.2. Cell Culture        72 
4.3.3. RT-PCR        72 
4.3.4. Real-time Polymerase Chain Reaction (TaqMan® Assay) 74 
4.3.5. Sequencing of SLC9A3 (NHE3), DPPIV, GLP-1R and  
 GAPDH PCR products      74 
4.3.6. Confocal microscopy      75 
4.3.7. Immunohistochemistry      75 
4.3.8. Western blot analysis      76 
4.3.9. Functional assays       77 
4.3.10. Cytotoxicity assay       78 
4.3.11. Statistical analysis       78 
4.4. Results          78 
4.5. Discussion          81 
 
 
5. Conclusions and outlook        87 
 
6. References          88 
 
Curriculum vitae                  100 
 
 
 
 
 
- 10 - 
Summary 
 
Overview kidney 
Kidney is, beside the liver, one of the most important organs for the elimination of 
waste products, toxins, drugs and their metabolites. Due to the anatomy of the 
kidney, ultra filtrate leaving the glomerulus passes first the proximal tubular cells. 
Therefore, these cells are exposed to high concentrations of xenobiotics which 
explains their high metabolic activity. This circumstance results sometimes in 
proximal tubular nephrotoxicity. In addition, various transmembrane proteins 
respectively transporters are responsible for the elimination or accumulation of drugs. 
This complex interplay is also responsible for drug-drug interactions. 
Therefore, proximal tubular cells are an interesting tool to study drug transport in the 
kidney. These cells are mainly localised in kidney cortex which makes it easy to 
isolate them (Fig. 1.1). Further isolation procedures enables high purity of proximal 
tubular cells by excluding connective tissue cells, distal tubular cells and other 
undesirable cells (elucidated in detail in 2.4).  
 
Aim of the thesis 
The aim of this thesis was to establish and validate a new in vitro model for drug 
transport in kidney by using primary porcine proximal tubular cells.   
In a first step, primary porcine proximal tubular cells were isolated from pig kidney, 
which were retrieved freshly at the slaughterhouse. These isolated cells were 
investigated to verify their origin from proximal tubular cells. In a next step the cells 
were screened at mRNA, protein and functional level for functional expression of 
important drug transporters. Finally, it was investigated if this model can be used for 
screening of drug-drug interactions or for specific drug transporter properties. 
 
Expression of drug transporters 
In cultured cells the following drug transporters were expressed (chapter 2.5 and 3.4) 
 
A) at mRNA level: 
 
• abcb1 (pMDR1) 
• abcc1 (pMRP1) 
• abcc2 (pMRP2) 
• slc22a8 (pOAT3)  
• slco1a2 (pOATP-A)  
• slc15a1 (pPEPT1) 
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• slc5a2 (pSGLT2)  
• slc4a4 (pNBC1)  
• slc9a3 (pNHE3)  
• abcg2 (pBCRP alias BMDP) 
 
B) at protein level 
 
• slc4a4 
• abcb1 
• abcc1 
• abcc2  
• abcg2 
 
C) functionally  
 
• abcb1: transport and uptake of digoxin, inhibition of digoxin transport and higher 
digoxin uptake with verapamil 
• abcc1: uptake of methotrexate, higher methotrexate uptake with indomethacin and 
MK571 
• abcc2: uptake of methotrexate, higher methotrexate uptake with MK571 
• slc22a8: transport and uptake of fluorescein, inhibition of fluorescein transport and 
uptake with estrone sulfate 
• slc15a1: transport and uptake of glycylsarcosine, inhibition of glycylsarcosin 
transport and uptake with benzylpenicillin 
• slc5a2: uptake of glucose, inhibition of glucose uptake with phlorizin 
• abcg2: uptake of mitoxantrone, higher mitoxantrone uptake with prazosin 
 
Slc22a1 (pOCT1) and slc22a6 (pOAT1) were only expressed in freshly isolated cells but 
were down-regulated in culture. Freshly isolated proximal tubular cells showed functional 
activity of slc22a6 as uptake of fluorescein was inhibited with p-aminohippuric acid.  
 
Confirmation of proximal origin 
Several transporters are expressed exclusively in proximal tubular cells. This fact was 
used in order to confirm the origin of the proximal tubular cells with each isolation. Due to 
expression of slc15a1, slc5a2, slc4a4, slc9a3 and the enzyme dipeptidylpeptidase IV 
(DPPIV, see below) we confirmed, that our cells are indeed of proximal origin. 
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BMPD expression 
After validation of the above mentioned drug transporters, we searched for possible 
inhibitors of BMDP/pBCRP, that might influence elimination of known BCRP substrates 
such as the chemotherapeutics topo- and irinotecan and mitoxantrone. The tested drugs 
included various antiepileptic agents, non-steroidal anti-inflammatory drugs, proton pump 
inhibitor, caffeine, theophylline, thalidomide and dotatoc. Of all investigated drugs, only 
phenytoin was able to inhibit BMPD significantly in our model.  
 
GLP-1 effect in proximal tubular cells 
Glucagon like peptide 1 (GLP-1) is an hormone, secreted after meal ingestion in the 
intestine. This peptide mediates satiety feelings and most importantly stimulates glucose 
dependent insulin secretion from pancreatic β-cells, thus lowering plasma glucose levels. 
Interestingly, GLP-1 also enhances renal sodium secretion in healthy volunteers. 
Therefore, we hypothesised that GLP-1 receptor (GLP-1R) is functionally expressed in 
proximal tubular cells. GLP-1R expression was confirmed at mRNA and protein level 
(chapter 4.4). More precisely, in kidney cortex the protein expression of GLP-1R seemed 
to be localised mainly in proximal tubular cells. Furthermore, we could show an inhibitory 
effect of GLP-1 on sodium re-absorption, indicating functional GLP-1R activity. In contrast 
to sodium re-absorption the re-absorption of glucose was not affected by GLP1. 
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Aim of the thesis 
 
Our objective was to establish and validate a new in vitro model for human drug transport 
in kidney. Though established cell lines of proximal tubular cells exist (e.g. LLC-PK1, HK-
2, killifish renal tubules), they are either immortalised and often transfected or the 
assessment of functional bidirectional transport is not possible. With primary proximal 
tubular cells a more “in-vivo” like situation, where various drug transporters are expressed 
simultaneously, is established. We decided to use primary proximal tubular cells from pigs 
since this material is easy to obtain. Furthermore, pig seems to be physiologically more 
closely related to human than other species such as dog, rat, mouse and rabbit.  
 
A first aim was to establish a cell culture model of primary proximal tubular cells from 
porcine. Therefore, fresh porcine kidneys were obtained from the slaughterhouse followed 
by an immediate isolation procedure. The origin from proximal tubular cells of these 
isolated cells had to be verified. 
A next aim was to investigate if important drug transporters of proximal tubular cells are 
functionally expressed in our cell culture model. Therefore a screening of various known 
drug transporters had to be performed at mRNA and protein level. In addition, uptake 
and/or transport assays had to be carried out in order to show in-vitro functional activity of 
these proteins. 
A next aim of the thesis was to investigate for the first time the functional expression of the 
porcine homologue of breast cancer resistance protein (BCRP/BMDP) in proximal tubular 
cells. Furthermore, we aimed at a functional discrimination of BMDP and P-gp activity. 
Therefore, cells had to be screened as mentioned above. For uptake assays specific 
substrates and inhibitors for BMDP and P-gp should be used. 
 
Another aim was to investigate the functional expression of glucagon like peptide receptor 
in proximal tubular cells. Therefore, proximal tubules had to be screened for GLP-1R at 
mRNA and protein level. In order to measure sodium concentration with fluorescence, a 
method had to be established. Then the effect of GLP-1 in proximal tubular cells on 
sodium and glucose re-absorption had to be investigated. 
 
With such an validated in-vitro model expressing various functional transporters 
simultaneously, it would be possible to predict tubular excretion rates, nephrotoxicity and 
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drug-drug interactions in an early stage of drug discovery and development more 
realistically.  
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1. Introduction 
 
1.1. Kidney – an overview 
In mammalians, the kidney is a pivotal control organ for the homeostasis of fluids, 
electrolytes, proteins and glucose. Excess of water and substances results in enhanced 
excretion. However, a lack of water and electrolytes causes the kidney to enhance re-
absorption, but maintaining the excretion of waste products, toxic products and drugs. In 
kidney, xenobiotics undergo three different processes: glomerular filtration, tubular 
secretion and tubular re-absorption. Secretion and re-absorption are mediated by 
transmembrane transport proteins of renal tubular epithelial cells and are therefore 
saturable [7]. As these processes often have to be maintained against concentration 
gradients, they are energy- respectively ATP-dependent. Proximal tubular cells are 
typically exposed to highest concentrations of xenobiotics, as the ultra filtrate leaves the 
glomerulus and flows (first) to the proximal tubule (Fig. 1.1). In addition, highest drug 
metabolising activity occurs in the kidney in proximal tubular cells explaining nephrotoxicity 
to be found often in these cells [10].  
Fig. 1.1 – Localisation of proximal tubular cells in the kidney. 
Adopted from [1]. 
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1.2. Transporters 
Cellular drug transporters 
are integral membrane 
proteins acting as 
gatekeepers for cells and 
organelles. They control 
uptake of important 
nutrients such as sugar, 
amino acids and 
nucleotides into cells and 
efflux of xenobiotics out 
of the cells. Typically 
these membrane proteins 
have 12 transmembrane 
domains. Two most 
important groups of 
transporters exist: ATP-
binding cassette (ABC) 
and solute carrier (SLC) 
transporters (Fig. 1.2). The ABC family transporters consist of 1200-1500 amino acids with 
a molecular weight of 140-180kDa, while the SLC family includes 300-800 amino acids 
with 40-90kDa [11].  
Fig. 1.2 – Expression of SLC and ABC transporter in the membrane or 
in intracellular compartments. Non SLC transporters can also be 
localised intracellular. Adopted from [2]. 
In contrast to passive transporters facilitating the passage of e.g. nutrients down their 
electrochemical gradients, ABC proteins are directly dependent on ATP in order to 
transport solutes actively against their concentration gradient. 
They are also called primary active transporters, as secondary active transporters (e.g. 
some SLC transporters) use ion gradients, previously established by ion pumps, in order 
to transport their substrates against their gradient [2].  
One of the two ATP binding domains of the ABC protein, also called nucleotide-binding 
fold/domain (NBF), possesses characteristic Walker A and B motifs [12]. In between those 
two conserved NBFs, located in the cytoplasm, ATP is trapped like a sandwich. A 
functional ABC protein, a full transporter, typically contains two NBFs and two 
transmembrane domains (TM) [13]. Half transporters must dimerise in order to gain 
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functionality. These TMs, containing 6-11 membrane spanning α-helices, determine 
substrate specificity. 
 
ABC transporters are divided into seven subfamilies ABCA-ABCG, depending on gene 
similarity, sequence homology in the TM and NBF domains, the order of the domains. In 
the following, a short overview is given for those subfamilies which are not mentioned in 
1.2.1.-1.2.3. [13, 14]:    
 
ABCA 
This subfamily covers 12 full transporters of which 5 are localised on the chromosome 
17q24 (ABCA5, 6, 8-10) and expressed in skeletal muscle, heart, ovary and in the liver. 
ABCA1 protein manages cholesterol transport and influences membrane plasticity and 
fluidity. ABCA4, found in photoreceptor cells, transports Vitamin A derivatives and 
influences therefore vision. 
 
ABCD 
Four genes belong to the ABCD subfamily, often associated with ALD 
(adrenoleukodystrophy). This half transporters are only expressed in the peroxisomes 
which have to homo- or heterodimerise. These substrates are transport long chain fatty 
acids.  Namely ABCD1 seem to be responsible for the X-linked form of ALD, as patients 
accumulate unbranched saturated fatty acids in their cells.  
 
ABCE & ABCF 
The ATP-binding domains of these two subfamilies derive from ABC transporters, however 
they do not possess a TM domain. To date ABCE and ABCF are not known to be involved 
in membrane transport functions. The oligo-adenylate-binding protein, OABP, the only 
member of ABCE, recognises oligo adenylate produced by some viruses indicating a 
probable involvement in immune answers. Each ABCF gene has a pair of NBFs. The best 
characterised gene is GCN20, found in S. cerevisiae, mediating the activation of eIF-2α 
kinase, a translation initiation factor. ABCF1, a human analogue, seems to exert similar 
effects.  
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The SLC family includes passive 
transporters, ion coupled transporters 
and exchangers. Some of these 
transporters are also located 
intracellular (see Fig. 1.2). If a 
transporter has <20-25% amino acid 
sequence homology to other 
transporters in the SLC family, it is 
assigned to this family.  A overview of 
different members of the SLC-family is 
given in table 1.1. SLC members which 
were found in porcine proximal tubular 
cells are mentioned below (see 1.2.4-
1.2.9).  
 
1.2.1. ABCB1 (MDR 1 alias P-gp) and 
members of ABCB 
To date, four full and seven half 
transporters compose the ABCB family, 
of which ABCB1 was first discovered 
and characterised in drug resistant 
tumour cell lines. ABCB was found to 
extrude cytostatic drugs out of the cells 
[14].  
ABCB1 consists of two similar regions, 
each containing six putative 
transmembrane segments and an 
intracellular ATP binding site [15]. Later, 
functional activity of ABCB1 was found in s
kidney and intestine [13]. In the kidney, ex
of proximal tubular cells [7]. Therefore, A
either reducing absorption at the intestine
back into the gut or by enforcing renal secrTable 1.1 - Overview of the SLC family adopted from [2].everal tissues such as blood-brain barrier, liver, 
pression was localised in the apical membrane 
BCB1 protects the body from xenobiotics by 
 as it pumps out already absorbed substances 
etion into urine. 
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A broad diversity of hydrophobic compounds are actively secreted by ABCB1, e.g. vinca 
alkaloids, digoxin, anthracyclines, steroids, cyclosporines, tacrolimus, HIV-1 protease 
inhibitors and organic cations [7, 14] which explains the importance of this transporter in 
drug-drug interactions and reduced bioavailability. A remarkable example is a small clinical 
cross over study with 12 healthy male receiving ritonavir for 11 days, digoxin was given on 
day 3 [16]: Ritonavir increased digoxin AUC (area under the plasma concentration-time 
curve) by over 80%, decreased the renal digoxin clearance by 35% and thus increased 
half-life by 156%. Another possibility for an unwanted increased AUC of digoxin is the 
most prevalent SNP (single nucleotide polymorphism) C3435T in ABCB1, which resulted 
in lower expression of this protein and higher digoxin plasma levels [17].   
Further essential ABCB transporters are 4 and 11 located in the liver and responsible for 
the secretion of phosphatidylcholine and bile salts, as mutations result in numerous forms 
of progressive familial intrahepatic cholestasis [14]. ABCB2 and 3 form heterodimers 
translocating foreign proteins into the endoplasmatic reticulum, where these antigens form 
complexes with class I histocompatibility proteins in order to present them on cell surfaces 
[14]. As one can imagine, defects in these areas result in a suppressed immune system.  
The remaining ABCB transporters, except for ABCB5, whose function has not been 
described to date and is expressed in all cells, are found in the lysosome (ABCB9) and in 
the mitochondria (ABCB6-8, 10) [14]. Their functions are partly unknown, though ABCB6 
and 7 are closely related and responsible for the transport of a precursor of the Fe/S 
cluster from mitochondria to the cytosol [13]. Gene mutations in the ABCB7 are found in X-
linked sideroblastic anemia and ataxia patients [14]. 
  
1.2.2. ABCC1-6 (MRP 1-6) and members of ABCC 
The ABCC family includes 12 full transporters managing ion transport, cell-surface 
mediated processes and toxin secretion [13]. Nine of them are MRP (multidrug resistance 
protein) related genes, of which ABCC1-3 transport glutathione conjugates and organic 
anions. The isoforms 4, 5, 11 and 12 are smaller than the other MRP transporters without 
a N-terminal domain, that is not required for transport function [13]. ABCC4 and 5 
translocate nucleosides.  Cystic fibrosis is caused by a mutation of the ABCC7 alias CFTR 
protein, which is a chloride ion channel and responsible for the exocrine secretion [14]. 
ABCC8 is a high affinity receptor for the drug sulfonylurea, an oral anti-diabetic drug. After 
binding of sulfonylurea an associated potassium channel is inhibited, that modulates 
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insulin secretion [13, 14]. Sulfonylurea binds with low affinity to the closely related ABCC9 
protein, regulating potassium channels in muscle [13].  
The authors in [6] give an excellent overview of substrates for MRP1-6 and their inhibitors: 
In general, these transporters translocate different substances such as leucotriene C4 and 
D4, MTX, PAH, anti-HIV drugs, vinca alkaloids, indomethacin  and estradiol-17β-D-
glucuronide. Typical inhibitors are probenecid, indomethacin and MK571.  
Interestingly, ABCB1 (MDR1) and ABCC1 (MRP1) share overlapping  substrate specificity, 
e.g. anthracyclines, vinca and colchicine alkaloids, with the difference, that ABCC1 is able 
to translocate glutathione conjugated drugs [13]. ABCB1 prefers large uncharged 
hydrophobic or slightly positively charged substances, whereas the MRP family prefers 
hydrophobic anions [18]. Furthermore, ABCC1 mediates inflammatory responses as it is 
capable of transporting leukotrienes. This transporter was found in various tissues, 
especially in liver, lung and kidney [7].  
ABCC2 is expressed in canalicular cells in the liver, often referred as cMOAT (canalicular 
multispecific organic anion transporter), in the kidney at the apical side of proximal tubular 
cells as well as in the intestine [19]. In the liver, it contributes to a great part to extrusion of 
organic anions e.g. bilirubin into the bile. The TR rat, which suffers under chronic 
hyperbilirubinemia, has a mutation in its abcc2 transporter [20]. The correlation of an 
ABCC2 mutation with Dubin-Johnson syndrome, a form of hyperbilirubinemia, was shown 
in human patients, too [21].   
ABCC3 was found in liver, colon, pancreas and to a lesser extent in the kidney [7], while 
ABCC4 was detected in several tissues, in the kidney at the apical side of proximal tubular 
cells [22]. Interestingly, both apically localised ABCC2 and 4 transport PAH, a prototypical 
substrate for renal organic anion transporters, with KM of 2mM respectively 160µM [23]. 
However, ABCCs seem to play a minor role in this regard, as KM values of PAH in 
SLC22A6 and A8 are significantly lower (see 2.6.6). More clinical relevant is the fact, that 
ABCC2, 4 and 5 are responsible for the renal elimination of antiviral drugs in the kidney, 
playing an important role in drug-drug interactions, (nephro) toxicity and resistance to 
nucleoside analogues (e.g. AZT) [6, 13].  
ABCC5 is ubiquitously expressed in tissues, including kidney, and translocates the 
antiviral agent adefovir, cAMP and cGMP [6]. Interestingly, ABCC5 and 
phosphodiesterase 5 (PDE5) are co-expressed in smooth muscle cells of the corpus 
cavernosum, indicating a second catabolic pathway of cGMP besides the PDE5 [24]: For a 
penile erection the increase of intracellular cGMP is mandatory. Sildenafil (Viagra) reduces 
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the degradation of cGMP by PDE5 thus inducing and prolonging erection. As sildenafil is 
translocated by ABCC5 [6] which also exports cGMP out of cells, a secondary mechanism 
of sildenafil action might be postulated: The inhibition of cGMP transport out of the cell and 
thus increasing intracellular cGMP.  
ABCC6 was mainly found in kidney and liver and translocates BQ123 (endothelin receptor 
blocker), so far this is its only known substrate besides LTC4 [6]. Unfortunately, a mutation 
(R1141X) in ABCC6 is related with a connective tissue disorder, called pseudoxanthoma 
elasticum (PXE), characterised by calcification of connective fibres in skin, arteries and 
retina leading to loss of elasticity, cardiovascular disease and ocular bleeding [25]. Another 
mutation, R1268Q, has been correlated with high plasma triglyceride and HDL levels [26]. 
 
1.2.3. ABCG2 (BCRP) and members of ABCG 
The ABCG family consists of six “reverse” half transporters, as the NBF is at the N 
terminus and the TM domains at the C terminus, an orientation which is contrary in other 
eukaryotic ABC proteins [14].   
The authors in [13, 14] provide a good overview of this family:  
ABCG1 is the human homologue to Drosophila white gene, with an amino acid identity of 
31%. The latter is the first gene found in this family. Therefore the ABCG family is often 
named as white half transporter family. The Drosophila white gene is a transporter for eye 
pigment precursors. ABCG1 is involved in cholesterol transport, similar to ABCG5 and 8 
(expressed in intestine and liver), genes which are mutated in patients with sitosterolemia 
(defective transport of dietary sterols such as sitosterol, stigmasterol, compesterol, etc…).  
To date ABCG3 has been exclusively found in rodents, ABCG4 is mainly expressed in 
brain [27]. For both transporter, their function is still unknown. 
ABCG2 was discovered as a multidrug resistance gene and is to date eagerly under 
investigation. ABCG2 has been made responsible for resistance to anthracycline drugs 
(doxorubicin and daunorubicin), mitoxantrone and camptothecin derivatives 
(topoisomerase I inhibitors e.g. topotecan and irinotecan) [28]. Interestingly, ABCG2 
transports also estrone-3-sulfate (known as SLC22A8 substrate), methotrexate (a classical 
ABCC1-3 substrate) and 17β-estradiol 17-β-D-glucuronide (free estradiol: ABCC2-4 and 
ABCB1 substrate) [29].  
At protein level, ABCG2 expression was found not only in carcinogenic cell types, but also 
in normal human tissues e.g. lung, bladder, prostate, uterus, intestine, pancreas, kidney 
and liver [30]. In kidney, the authors in [30] could sub-localise ABCG2 to cortical tubules, 
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while in mouse kidney it was found at the apical side of proximal tubular cells [31]. 
Furthermore its expression was detected in the placenta, suggesting a protective function 
for the foetus [14].  
As all ABCG transporters are half transporters, they have to form either homo- or 
heterodimers in order to gain functionality. ABCG2 is supposed to build a homodimer [32]. 
Interstingly, abcg2 knock out mice developed symptoms similar to protophorphyria, as a 
degradation product of chlorophyll, called pheophorbide induced severe dermal phototoxic 
lesions after light exposure [33].  Therefore ABCG2 seems to be responsible for reducing 
uptake of pheophorbide, found in numerous plant-derived foods and food supplements, 
after meal ingestion. In addition, abcg2 knock out mice had a threefold higher AUC after 
oral intake of the food carcinogen PhIP (2-amino-1-methyl-6-phenylimidazo[4,5-
b]pyridine), demonstrating ABCG2’s role in protecting the body from toxic compounds [34]. 
Its role could be even more crucial as that of ABCB1, since in human jejunum the mRNA 
level of ABGC2 was higher compared to ABCB1 [35]. Analyses of human sequences 
revealed numerous (over 80) different variations, of which two can be called as 
polymorphic forms (V12M and Q141K) of ABGC2 in several populations [32]. Though 
many investigations have been performed regarding expression, localisation and function, 
the results are contradictory and to date it is not possible to pose a clear statement [32].  
 
1.2.4. SLC4A4 (NBCe1) 
In the SLC4A family are to date 11 members known, which can be divided, dependent on 
their function, into three groups, [36]: 1. Cl-/HCO3- exchangers; 2. Na+/HCO3- 
cotransporters (NBCs); and 3. Na+ dependent Cl-/Na+HCO3- exchangers (NDCBEs). 
SLC4A11 (alias BTR1 or NaBC1) represents an exception, as it translocates borate Na+-
dependently and can’t be classified in one of the three gropus. It was included in the SLC4 
family due to its homology with other members of this family. 
The second group, Na+/HCO3- cotransporters (NBCs), can be divided further into a 
electroneutral group with a HCO3- (or CO32-) : Na+ stoichiometry of 1:1, while the 
electrogenic cotransporters translocate with a stoichiometry of 2:1 or 3:1.  A stoichiometry 
of 3:1 favours energetically extrusion of bicarbonate from cells while 2:1 stoichiometry 
favours cellular uptake [37]. Interestingly, rat kidney NBCe1 expressed in Xenopus laevis 
oocytes could change its stoichiometry from 2:1 to 3:1 after an calcium increase [38]. In 
murine proximal tubular cells the stoichiometry of NBCe1 shifted from 3:1 to 2:1 after 
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phosphorylation at position Ser982 [39]. Thus this transporters has the ability to shift 
between influx and efflux of bicarbonate.  
In humans, two splice variants have been found  [36]: kNBC1, which is highly expressed 
on the basolateral membrane of proximal tubular cells, and pNBC1 highly expressed in 
pancreas and at lower level in various other tissues, e.g. kidney, brain, liver, prostate, 
colon, stomach, thyroid, and spinal chord [40]. Intriguingly, more than 85% of the filtered 
load of HCO3- is re-absorbed in proximal tubular cells, accomplished by an apical Na+/H+ 
exchanger and the basolateral SLC4A4 [41]. 
As SLC4A4 is crucial for the acid-base regulation, mutations in the human gene resulted in 
metabolic acidosis [41]. Furthermore, mental retardation, short stature and ocular 
abnormalities have been described with mutations in this gene [37].   
The other familiy members of SLC4, such as SLC4A1-3 (AE1-3), SLC4A5 (NBC4 or 
NBCe2), SLC4A7 (NBC3 or NBCn1), SLC4A8 (NDCBE), SLC4A9 (AE4), SLC4A10 
(NCBE) and SLC4A11 (NaBC1) were partly found in kidney but have to date not been 
localised in proximal tubules [36, 37].  
 
1.2.5. SLC5A1/2 (SGLT 1/2) 
The SLC5A family consists amongst others of six sodium-dependent glucose transporters, 
which are secondary active transporters translocating glucose (and other 
monosaccharides) against its concentration gradient into cell. The driving force here is, 
similar to the SLC9A family, the inwardly directed Na+ gradient established by the Na+/K+ 
ATPases [42].  
The high affinity, low capacity transporter SLC5A1 (SGLT1) has been found in intestine 
and in renal proximal tubules (S3 cells) with a Na+ to glucose coupling ratio of 2:1 [43]. In 
this part of the renal tubules (S3) SLC5A1 is expected to re-absorb remaining glucose, 
which has not been re-absorbed completely by the high capacity, low affinity transporter 
SLC5A2 (SGLT2), mainly located at the apical side of proximal tubules (S1 and S2 cells) 
and mediating Na+ to glucose with a ratio of 1:1 [44]. The third renal transporter SLC5A4 
(SGLT3), probably located at an earlier segment of proximal tubules, is a high capacity 
transporter similar to SGLT2 but with the same Na+/glucose stoichiometry as SGLT1 of 2:1 
[45]. Recently, SLC5A9 (SGLT4) has been found to some extent in human kidney (with a 
higher mRNA than SGLT1), however its exact localisation has to be elucidated [46]. 
SLC5A10 (SGLT5) has been found in bovine kidney [47]. The sodium-dependent glucose 
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transporter SLC5A11 (SGLT6 alias KST1 or SMIT2) seems to be expressed in various 
tissues [48].  
Mutations of human SLC5A1 (SGLT1) led to a glucose / galactose malabsorption resulting 
in severe diarrhoea and dehydration [49], indicating, that in the intestine, SGLT1 seems to 
be the major glucose absorbing transporter. However, SLC5A4 (SGLT3 former SAAT1) 
has been also detected in pig intestine (at mRNA level) [50]. As one would expect, 
mutations in the SLC5A2 gene result in renal glucosuria [51]. Other mutations in sodium-
dependent glucose transporters are to date not known.  
The facilitative Na+-independent sugar transporters GLUT 2, 5, 9 belonging to the SLC2A 
family are also present in kidney [42]. GLUT2 and 5 are fructose transporter. The latter has 
been localised at the brush border membrane of the S3 proximal tubules in rats [52]. 
However, GLUT2 is found at the basolateral side of proximal tubules and is also 
transporting glucose with low affinity [42]. Recently, GLUT1 and 12 has been found in 
kidney: in rat GLUT1 was located basolateral throughout the nephron, whereas GLUT12 
was found at the apical side in human and rat distal tubules and collecting ducts [53]. Their 
main function is to facilitate transport of glucose and other sugars (e.g. fructose) along 
their concentration gradient.  
 
1.2.6. SLC9A3 (NHE 3) 
To date, nine members of the SLC9A family (Na+/H+ exchange respectively NHE family) 
are known [54-56]. However, at www.gene.ucl.ac.uk/cgi-bin/nomenclature/searchgenes.pl  
eleven members are described. These secondary active transporters regulate intracellular 
pH, cell volume, systemic electrolyte, acid-base and fluid volume homeostasis by 
exchanging Na+ into cell with H+ out of cell. Their driving force is accomplished by Na+/K+ 
ATPase pumps which establish the inward Na+ gradient. The SLC9A family can be divided 
into five isoforms SLC9A1-5 located at the plasma membrane and the intracellular 
organellar forms SLC9A6-9 [57]. Interestingly, SLC9A3 and SLC9A5 cycle between 
endosomes and plasma membrane while the other three NHE1, 2 and 4 stay stationary.  
SLC9A1, 6-8 are ubiquitously expressed, whereas other SLC9A members are expressed 
in various tissues such as stomach, intestine, skeletal muscle and brain [56]. SLC9A1-4 
and 8 have been found in kidney [58]. NHE3 is located predominantly in kidney proximal 
tubule, at the luminal/apical side [58]. There, NHE3 is crucial for Na+ and water re-
absorption [59]. The associated secretion of H+ contributes to a major part (approx. 66%) 
of renal HCO3- re-absorption [60]. Interestingly, NHE3 forms complexes with other 
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proteins, such as CHP1/2, megalin, dipeptidylpeptidase IV (DPPIV) and PDZ-proteins 
(post synaptic density protein, Drosophila disc large tumour suppressor, and zo-1 protein). 
CHP are calcineurin B homologous proteins which are vital for the activity of NHE3 [61, 
62]. NHE3 exists in two forms: either active in microvilli or inactive, when megalin 
associated, in intermicrovillar microdomains of the apical plasma membrane [63]. DPPIV 
inhibitors such as P32/98 reduce NHE3 activity significantly, although the mechanisms 
behind this action remains unclear [58]. The PDZ proteins NHE-RF1 / 2 inhibit NHE3 in a 
cAMP dependent way [64, 65]. 
Loss of NHE3 function has been associated with diarrhea characterised with Na+ enriched 
alkaline stools, hyponatremia and metabolic acidosis [66]. This finding correlates with 
NHE3 knock out mice [67, 68]. Furthermore these results demonstrate the significance of 
SLC9A3 in the intestine and kidney regarding systemic homeostasis of electrolytes, acids 
and bases as well as blood pressure.    
  
1.2.7. SLC15A1/2 (PEPT 1/2) 
The SLC15A family consists of four peptide transporters: PEPT1 (SLC15A1), PEPT2 
(SLC15A2), PHT1 (SLC15A4) and PHT2 (SLC15A3) [3]. They all transport di- and 
tripeptides into intestinal and renal epithelial cells, whereas only PHT1 and 2 are capable 
of translocating free histidine. PEPT1 is mainly expressed in the small intestine, in the S1 
segment of proximal tubules and in bile duct epithelial cells and has been characterised as 
high-capacity, low-affinity peptide transporter [69-71], whereas PEPT2 has its predominant 
expression in the S2 and S3 segment of proximal tubules as a low-capacity, high-affinity 
transporter [72]. Interestingly, this topographic arrangement of first, a high-capacity, then a 
low-capacity but high affinity peptide transporter in the proximal tubules is similar to the 
glucose dependent SGLT1/2 transporters (see 1.2.5.). PEPT2 was also found in brain 
astrocytes, mammary lands and in the lung [73-75]. The histidine/peptide transporter 
PHT1 was found in rat brain and human placenta, whereas PHT2 was found in various rat 
tissues, such as lymphatic system, spleen, lung and thymus [76].  
The driving force for the re-absorption of di- and tripeptides in proximal tubular cells is the 
inwardly directed H+ gradient, established by the prior mentioned sodium-proton 
exchanger NHE3 (SLC9A3) [3]. The influx of sodium is compensated by the Na+/K+-
ATPases at the basolateral side, pumping 3 Na+ out of the cell in return of 2 K+ into cell, 
the latter leaving the cell by potassium channels. The re-absorbed peptides, respectively 
amino-acids, as the peptides are rapidly degraded by intracellular peptidases, are then 
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transported out of the cell at the basolateral side by a not yet defined peptide transporter 
(Fig. 1.3).   
For PEPT1, the coupling ratio of protons with neutral and cationic peptides is 1:1 and for 
anionic peptides 2:1 [77, 78]. PEPT2 transports neutral peptides together with 2 protons, 
anionic peptides together with 3 protons and cationic peptides are transported together 
with a variable numbers of protons [79].  
PEPT 1/2 transport also various beta-lactam antibiotics [80-82], oral antidiabetics, such as 
glibenclamide [9], ACE inhibitors, the anticancer drug bestatin and other peptidomimetics 
such as valacyclovir [7]. It is quite obvious that concomitant use of the above mentioned 
drugs results in 1. reduced absorption of the drug in the intestine and 2. influences the 
Fig. 1.3 – Uptake of di– and tripeptides (upper compartment) and of peptidomimetics into cell. Adopted from 
[3].  
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pharmacokinetics as renal clearance might be enhanced due to reduced re-absorption in 
proximal tubular cells.  
To date, neither pathology associated with malfunction of these transporters nor 
polymorphism are known in humans [3]. However, PEPT1 is expressed in inflamed colonic 
tissues and is capable to transport the known neutrophile attractant peptide formyl-Met-
Leu-Phe derived from certain bacterial species [83, 84]. 
 
1.2.8. SLC21A (SLCO alias OATP) 
In order to cope with the rapid growth of the SLC21A family, a new species independent 
classification and naming system has been introduced: In the OATP / organic anion 
transporting protein family, 21A has been replaced by O (letter) [2]. In the following, both 
nomenclatures inclusive aliases are used. 
To date, 14 rat and 11 human Oatps/OATPs have been identified [85]. Although some 
OATPs are restricted to liver only, e.g. SLCO1B1 (SLC21A6 alias OATP-C) and SLCO1B3 
(SLC21A8 alias OATP8) managing uptake of bulky and relative hydrophobic organic 
anions, most OATPs are expressed in various tissues such as kidney, brain, heart, lung, 
placenta and testes [86].  
Typical OATP substrates are mainly amphipathic molecules with a high molecular weight 
(>450kDa), e.g. bile salts, steroid hormones and their conjugates, substances which are 
often bound to albumin [86]. In humans, only SLCO4C1 (SLC21A20 alias OATP4C1) is 
expressed in the kidney. This transporter is located at the basolateral side of the proximal 
tubules where it translocates digoxin, ouabain and T3 (triiodothyronine) from blood into the 
proximal cells [85, 87]. 
OAT-K1/K2 are transporters found specifically in rat kidney, while human orthologs are to 
date not existent [85]. These two transporters are located at the apical side with a narrow 
substrate specificity such as MTX (methotrexat), AZT (azidothymidine), folate and digoxin 
[6].  
The first characterised human OATP was SLCO1A2 (SLC21A3 alias OATP-A) and was 
found at mRNA level in the brain, liver and kidney [6]. This transporter translocates various 
compounds such as bile salts, hormones and their conjugates, prostaglandine E2, 
peptides (endothelin receptor antagonist BQ-123, thrombin inhibitor CRC-220, opioid 
receptor agonist d-penicillamine 2, 5-enkephalin), fexofenadine, N-methylquinine and N-
methylquinidine [86]. 
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All OATPs transport the above mentioned substances sodium independently [86]. In 
addition, there is evidence for an anion exchange mechanism between organic anions and 
GSH (glutathion) functioning as driving force, although this has only been shown for the 
mouse/rat Oatp1 and Oatp2 [86].  
 
1.2.9. Overview of the SLC22A family 
The SLC22 family (to date A1-A18) includes not only the organic cation / anion 
transporters but also organic carnitine transporters OCTN 1/2, CT2 (SLC22A4/5, A16) and 
URAT1 (SLC22A12), responsible for urate transport in the kidney [88]. Further SLC22 
members are FLIPT 1/2, BOCT and ORCTL2-4, all organic cation transporters. Most of the 
previously mentioned transporters are expressed in kidney, especially in proximal tubular 
cells [5, 8, 11, 85].  
Small (<500kDa) and hydrophilic organic anions are mainly excreted via the kidneys, 
whilst large (>500kDa) and hydrophobic anions favour the excretion pathway by the liver 
[85]. 
In order to excrete organic anions / cations from blood into urine, it is mandatory to enable 
the entrance of organic anions / cations at the basolateral (blood) side of e.g. proximal 
tubular cells and the excretion at the apical (urine) side. Therefore, organic anion / cation 
transporters are located on both cellular sides. In figure 2.1, the localisation of the 
transporters in proximal tubular cells is given: SLC22A6-8 and SLC22A1-3 are located 
basolaterally (blood side), whereas SLC22A10-11 and SLC22A2, too, are located apically 
(urine side). Following example illustrates that the SLC22 family members do not only 
function as eliminators of organic anions / cations but also withhold important substances: 
Carnitine, a vital co-factor of mitochondrial β-oxidation [89], is an amine which is re-
absorbed by SLC22A4/5. Both transporters are located at the apical side and directed 
inwardly [90].  
 
1.2.9.1. SLC22A1-3 (OCT 1-3) 
Interestingly, SLC22A1-3 has to be regarded as a facilitative diffusion system that can 
transport cations in both directions. Transport direction is driven by its concentration 
gradients, dependent on the membrane potential and independent of sodium [8]. SLC22A1 
has been studied in different species (rat, mouse, rabbit and human) where it was mainly 
expressed in the liver. However in rodents, high expression of SLC22A1 was also found in 
kidney [91]. In contrast, SLC22A2 is mainly expressed in kidney, whereas SLC22A3 is 
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expressed in different tissues e.g. skeletal muscle, liver, placenta, kidney and heart [91]. 
SLC22A1-3 have a broad substrate specificity [91]. All three transporters translocate to a 
certain extent the following substances: β-estradiol, progesterone, cimetidine, clonidine, 
desipramine, prazosin, quinine, verapamil, MPP+ (1-Methyl-4-phenylpyridinium) and TEA 
(tetraethylammonium) [92]. The last two mentioned substances MPP+ and TEA are not 
used therapeutically but as model substances for SLC22A1-3 transport studies. 
Single nucleotide polymorphisms (SNPs) have been investigated and found in SLC22A1 & 
2 [92]: In 57 Caucasians, the most frequent polymorphism with 16% frequency (Arg61Cys, 
located at the large extracellular loop) resulted in a reduction of MPP+ uptake by half. More 
extreme, although less frequent, the mutation Cys88Arg (1.2%) and Gly401Ser (6.7%) 
demonstrated a MPP+ uptake of 2% of wild type SLC22A1. This fact is of clinical 
importance, as the uptake of cationic drugs and xenobiotics in liver is mediated by 
SLC22A1. A reduced activity of this transporter can be beneficial or devastating: 
beneficial, if the substance is toxic to the liver and is eliminated by other means (e.g. 
kidney) or devastating, if the substance is toxic for the body and can’t be 
eliminated/excreted fast enough, as the uptake into liver is reduced. Sixteen SNPs in the 
coding region of SLC22A2 were found, of which eight caused single amino acid 
substitutions and one resulted in a premature termination of the protein. Interestingly, 
Met165Ile and Arg400Cys led to an two – threefold higher uptake of MPP+ than wild type 
SLC22A2, which again can be beneficial in the kidney in order to excrete toxic xenobiotics 
faster or can be disadvantageous if a drug should stay in body.  
Anyhow, to date no specific disease or adverse drug reaction can be attributed to 
malfunction of SLC22A1-3, as substrate specificities and expression patterns are 
overlapping within these transporters and with other transporters [92], e.g. SLC22A8 
translocating cimetidine or ABCB1 mediating quinidine and verapamil [93-95].  
 
1.2.9.2. SLC22A6-8, 11, 10 (OAT 1-5) 
Many clinical important anions like β-lactam antibiotics, diuretics, NSAIDs (non-steroidal 
anti-inflammatory drugs), virostatics, anticancer agents and ACE (angiotensin-converting 
enzyme) inhibitors are substrates of the organic anion transporters (OAT 1-5) [5]. This 
demonstrates a broad substrate specificity for these SLC members. Translocation of 
various drugs/substrates are overlapping between different isoforms of organic anion 
transporters [4, 6, 85].  In general, renal tubular cells are negatively charged, therefore 
basolateral uptake of organic anions has to be accomplished against their electrochemical 
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gradient [6]. In order to achieve this aim,  Na+/K+ - ATPase pumps Na+ out of the cell 
establishing a gradient, which is used to co-transport Na+ with α-ketoglutarate through 
SLC13A3 alias SDCT (sodium/dicarboxylate cotransporter) into cell. Finally α-
ketoglutarate is exchanged by an organic anion and, therefore, the organic anion enters 
into the proximal tubular cells [5]. As the mechanism of the exit of organic anions at the 
apical side is not yet completely solved, different mechanisms are postulated, like 
involvement of the PAH (para-aminohippuric acid)/dicarboxylate or PAH/anion exchanger 
or a membrane potential dependent mechanism [5].  
The first discovered organic anion transporter was SLC22A6 in rat kidney [96, 97]. 
Functional activity was tested with the prototypic organic anion PAH, explaining why 
SLC22A6 is often referred as PAH transporter [85]. Expression of the human ortholog 
hOAT1 was also shown in skeletal muscle, placenta and brain [91].  
SLC22A7 (OAT2) was originally found in rat liver and was first named NLT (novel liver-
specific transporter) [7]. Rat OAT2 is highly expressed in liver but low expression was 
found in kidney [6]. Interestingly, SLC22A7 is not driven by the outwardly directed α-
ketoglutarate gradient [98]. The intrarenal distribution of OAT is not clearly solved yet, as 
rat OAT2 was localised to the apical side of renal tubular cells while human OAT2 was 
localised at the basolateral side of proximal tubular cells [6, 85].  
SLC22A8 was discovered in rat and human, in rat mRNA expression was found in liver, 
brain and kidney while in humans high levels of mRNA were detected only in kidney [6]. 
According to the authors in [91] hOAT3 is also expressed in brain and skeletal muscle and 
interestingly not in liver.  
SLC22A11 is abundantly expressed in kidney and placenta [85], whereas SLC22A10 
(hOAT5) mRNA was exclusively found in liver and rOAT5 was exclusively expressed in 
kidney [91]. Due to its low amino acid identity of 55% between hOAT5 and rOAT5 it is 
questionable if these two transporters are homologues [91].  
 
Drug-drug interactions involving OAT transporters are very likely, due to their broad 
substrate specificity. For example, intake of MTX (methotrexate), a cytostatic drug, with 
anionic drugs such as NSAIDs or β-lactam antibiotics, resulted in severe suppression of 
bone marrow as a result of reduced renal clearance of MTX [5]. 
Paradoxically, organic anion transporters, which detoxify our body from xenobiotics, can 
enforce nephrotoxicity of drugs, e.g. cephaloridine or oxytocin A, due to accumulation in 
proximal tubular cells [5]. Co-medication of substrates or inhibitors of the involved OAT 
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can decrease nephrotoxicity by a reduced renal excretion of the given drug leading to 
increased efficacy but also to increased adverse events [91].  
SLC22A11 (OAT4) secrets not only anions at the apical side of proximal tubular cells but 
also re-absorbs filtered prostaglandins [91]. Furthermore, OAT4 seems to excrete toxic 
anions from fetal into maternal circulation. Thus, an impairment of OAT4 can lead to a loss 
of prostaglandins and fetal intoxication. 
 
1.3. Proximal tubular cells – which species? 
It is clear that obtaining healthy human kidney is difficult and self-limiting. To date, little is 
known about species differences between e.g. human, rat, mouse, dog, rabbit, monkey 
and pig regarding renal drug transport. Monkey seems to be a good predictor model for 
renal drug-drug interactions in humans [99-101], whereas the dog remains a questionable 
alternative [102]. The authors in [10] emphasise that humans are physiologically more 
closely related to pig than to rat, rabbit or mouse. Taken this into consideration and the 
fact that porcine kidney is easily available, a validation of primary porcine proximal tubular 
cells seem to be an interesting alternative as an in vitro model for drug transport in human 
kidney.  
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2.1. Abstract 
Background: Kidney proximal tubular cells play a major role in the transport of endogenous 
and exogenous compounds. A multitude of different transporters are expressed starting 
with multidrug ABC transporters (e.g. abcb1, abcc1-6), slc22a6-8 (organic anion 
transporters) and slc22a1-3 (organic cation transporters). For transport studies of renal 
drug transport, cell lines like MDCK and LLC-PK1 are often used to overexpress and study 
one or two transporters, such as abcb1 or abcc1-6. However, the use is limited since 
under physiological conditions xenobiotics are transported through different transporters at 
the same time. Therefore, a primary in vitro model expressing functionally different 
transporters simultaneously, as it is the case in vivo, would be of great benefit. 
Methods: Primary proximal tubular cells were isolated from porcine kidney. Cells were 
cultured under selective culturing conditions leading to specific growth of primary proximal 
tubular cells. Expression of important proximal transporters was checked at mRNA level 
with RT-PCR, at protein level with immunocytochemistry and functionally by transport and 
uptake assays. 
Results: A model of primary proximal tubular cells was established expressing the most 
important transporters: abcb1, abcc1, abcc2, slc22a8, slco1a2, slc15a1, slc5a2 and 
slc4a4. In freshly isolated cells, slc22a1 and slc22a6 were expressed, but were down-
regulated in culture. Abcb1, abcc1, abcc2 and slc4a4 were detected at protein level with 
immunostaining. Functional activity was confirmed for abcb1, abcc1/2, slc22a8, slc15a1/2 
and slc5a1/2. The tightness of the monolayers of this model was better than in previously 
established in vitro models. 
Conclusion: This primary cell culture model might be an interesting tool to investigate 
proximal tubular transport and to predict toxicity and drug interactions since it expresses 
functionally several transporters simultaneously. 
 
2.2. Introduction 
Renal elimination of drugs and toxins is necessary for the survival of mammalian species. 
Regarding physiology of different species, humans are more closely related to pig, than to 
rat, rabbit or mouse [10]. Thus a porcine in vitro model might be more suitable for 
prediction of transepithelial drug transport, than other non-human species. The existing 
cell lines e.g. HK2 and HKC (human proximal tubular cells), HEK293 (human embryonic 
kidney), LLC-PK1 (proximal tubular cells from pig) and MDCK I/II (distal tubular cells from 
dog) would provide enough possible models to study renal elimination. However, these cell 
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lines are immortalised. The advantage of having a cell line for many passages available is 
diminished by the fact, that transporter or enzyme activities may have been changed. For 
example, in rabbit kidney proximal tubule, the activities of sodium-glucose co-transport 
system, gamma-glutamyl transpeptidase and alkaline phosphatase were reduced after few 
passages [103]. Also, signal transduction pathways seem to be more intact in primary 
cultures than in immortalised cell lines [104]. Many transport studies were performed in 
each of the above mentioned immortalised cell lines, which were transfected with 
transporters and thus altering the system [105-110]. As many different transporters are 
involved in the elimination of xenobiotics (Fig. 2.1), a transfection and thus over-
expression of one or more drug transporters ignores possible influences of other 
transporters. Using the parental cell line as reference, where transporters might be already 
partially down regulated in their function, is questionable. Therefore a primary cell culture 
Figure 2.1 - Different transporters in the proximal tubular cells as described in the literature [4-9]. 
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model expressing different drug transporters simultaneously like in the in vivo situation 
would be of great interest. 
In the following, an overview of different drug transporters in the kidney is given.  
In order to excrete large (amphophilic) drugs, transporters are needed to overcome the 
transepithelial barrier [6]. The expression of slc15a1/2 (peptide transporter PEPT1/2) [9, 
81] and slc5a1/2 (sodium-dependent glucose transporter SGLT1/2) [111] for the re-
absorption of important nutrients like amino acids, peptides and glucose from the urine is 
mandatory. The kidney is, together with the liver, the most important detoxifying organ [7]. 
In drug discovery and development, an in vitro model expressing the most important 
transporters concurrently would be an important tool in order to predict elimination, toxicity 
and drug interactions at a functional level. From all renal segments, the proximal tubular 
cells have the highest transport activity and are exposed to highest concentrations of 
xenobiotics [6, 10].  
Multidrug-resistance transporters (such as abcb1, respectively P-gp or abcc1-6, 
respectively MRP1-6) are important for proximal tubular secretion of many drugs. Abcb1 
interacts mainly with neutral and cationic xenobiotics (e.g. digoxin, cyclosporine A, 
vinblastin, antiviral drugs) [112]. Abcc1-6 have like abcb1 a broad substrate specificity 
[113]. Although abcc1-6 prefer anionic molecules many substrates are transported by 
both, abcb1 and abcc1-6 (especially neutral molecules and some polypeptides) [114]. 
Slc22a6-8 (organic anion transporters: OAT1-3) are transporting a broad spectrum of 
xenobiotics such as β-lactam antibiotics, antiviral drugs, diuretics, NSAIDs, PAH, estrone 
sulfate, fluorescein but also MTX (methotrexate), pravastatin and cimetidine [6, 115-120].  
The Slc21 family (organic anion transporting polypeptides: OATPs) interacts with bile 
acids, steroids, fexofenadine, estrone sulfate, pravastatin and antiviral drugs [5-7, 86].   
Slc22a1-3 (organic cation transporters: OCT1-3) are translocating a variety of cationic 
drugs such as procainamide, desipramine, clonidine, araC, cimetidine, nicotine, quinidine, 
verapamil, corticosterone, dopamine, epinephrine, 5-hydroxytryptamin, and amantadine [6, 
8, 121]. 
Slc15a1/2 (peptide transporters: PEPT1/2) are important for re-absorption of amino acids 
and oligopeptides [6]. Furthermore valacyclovir, glycylsarcosine, β-lactam antibiotics, ACE-
inhibitors, glibenclamide and dipeptide-like anticancer drug bestatin are substrates of 
these transporters [6, 9, 81, 82, 122]. Glycylsarcosine is used as a model substrate for 
slc15a1/2 [80]. Re-absorption of glucose and its derivates are managed through sodium-
dependent glucose transporters, which are classified in a high affinity Na+/Glucose co-
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transporter slc5a1 (SGLT1) und low affinity Na+/Glucose co-transporter slc5a2 (SGLT2) 
[111]. Both transporters can be inhibited by phlorizin. The facilitated-diffusion glucose 
transporter family (SLC2 respectively GLUT) is also expressed with different subtypes (1-
5) located on both sides of the proximal tubular cells (apical and basolateral) [123, 124]. 
The electrogenic Na+-HCO3– co-transporter slc4a4 (NBC1) located at the basolateral side 
of proximal tubular cells in the kidney is responsible for the re-absorption of NaHCO3 (80% 
through slc4a4) and regulation for acid base status [37, 125]. 
All these, and some other not mentioned transporters, contribute to the renal transport 
function to detoxify the body from xenobiotics or endogenous waste products.  
To study isolated transport of one transport protein, tumour cells derived cell lines are 
often utilised, which over-express e.g. either abcb1 and/or abcc1-6 [126]. However, to 
predict proximal tubular elimination, a more realistic model would be desirable. Therefore, 
it was our aim, to characterise functional expression of a primary cell culture based model 
of porcine proximal tubular cells expressing important transporters simultaneously.  
 
2.3. Materials 
[3H]glucose (573.5GBq/mmol) was purchased from DuPont NEN Research (Boston, USA), 
[3H]digoxin (865.8GBq/mmol) from Perkin Elmer Life Science (Boston, USA), [3H]MTX 
(1239.5GBq/mmol) and [14C]glycylsarcosine (4.07GBq/mmol) from Moravek Biochemicals 
(Brea, USA), [14C]PEG4000 (496MBq/g) from Amersham Bioscience (Buckinghamshire, 
England), MK571 from Biomol Research Labs (Plymouth Meeting, USA), Nycodenz from 
Axon Lab (Baden-Dättwil, Switzerland), MEM Eagle D-Valine w/L-glutamine from Lucerna 
Chem AG (Luzern, Switzerland), Dulbecco’s MEM / Nut Mix F-12 (DMEM/F12), Fetal calf 
serum (FCS) and penicillin/streptomycin from Gibco (Gibco Life Sciences, Basel, 
Switzerland), Insta-Gel Plus from Perkin Elmer (Boston, USA), cell flask 75cm2 from BD 
(Franklin Lakes, USA). All other substances were purchased from Sigma/Fluka in highest 
quality.  
 
2.4. Functional characterisation of transporters 
2.4.1. Cell Culture 
Porcine proximal tubular cells were isolated and seeded as described previously [127]. In 
brief, fresh pig kidneys with the capsule were retrieved in the slaughterhouse and put into 
ice-cold Eurocollins, pH 7.4 and 2mM glycine. The cortex was removed, minced and 
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washed with Ca2+ and Mg2+ free Hanks’ buffer, containing 25mM HEPES and 2mM 
Glycine (Buffer A). The washed cortex was then digested with collagenase (0.07%w/V) in 
buffer A with 1mM desferal and 4mM Ca2+ at 37°C for one hour. For 30g cortex 25ml of 
this buffer was used. The incubation was terminated with ice-cold buffer A including 4mM 
Ca2+ and 1.5% (w/V) bovine serum albumin (buffer C). All buffers contained 100U/ml 
respectively 100µg/ml penicillin/streptomycin. After filtration through an 80µm nylon gauze, 
washing, centrifugation (80g, 5min, 4°C) the cells were diluted in a Nycodenz solution with 
11.3% Nyocodenz.  Establishing a gradient of Nycodenz solutions with layers of 17%, 
11.3% (containing cortex cells) and 8.5%, all of them containing 6.7mM KCl, 1.22mM 
CaCl2 and 10mM HEPES, the mixture was centrifuged (2300g, 6min, 4°C). The cells at the 
interface between the upper two layers were harvested, washed (80g, 6min, 4°C) with 
buffer C. Viability was determined by tryptan blue exclusion. One ml cell suspension with 
1.5 ? 106 cells was cryoconserved in cell culture medium 1 (see below) with 10% DMSO.   
Cells were seeded (1.5⋅106 cells in 75cm2 flask) in 50ml of 9.6g/1000ml MEM D-Val, 10% 
FCS and 100U/ml penicillin/streptomycin (medium 1) and cultured for 5 days (after the first 
48h medium was changed every day). As in medium 1 proximal tubular cells can use D-
valine and fibroblasts do not, fibroblast growth was suppressed. Then culturing was 
continued with DMEM/F12 (containing L-Valine) with 10% FCS and 100U/ml 
penicillin/streptomycin (medium 2) until confluence was reached (about 3 days, medium 2 
was changed on the second day). For both medium conditions the cells were incubated at 
37°C in 95% air and 5% CO2. For passaging the monolayer was trypsinised with 10ml 
(trypsin EDTA from Gibco) for 15min. Then 10ml of medium 2 was added and centrifuged. 
After removing supernatant the cell pellet was diluted in medium 2. For transport studies 
cells were transferred onto uncoated Transwell filter cell culture systems. On Transwell 
filters tightness was reached after 3-4 days in medium 2, so that primary cells were 
cultured in total for 11-12 days. After this period the cells were discarded.  
 
2.4.2. Transepithelial electrical resistance (TEER) measurement  
TEER was measured with Millipore Millicell ERS (Volketsville, Switzerland). 
Measurements were carried out as described in the manufacturer’s description. The 
electrode was at least 24 hours in the same culture medium as the cells. The 
transepithelial electrical resistance (TEER) of blank filters in culture medium 2 was 146 ± 
4.7 Ω·cm2. There was a correlation between low FITC-dextran or [14C] PEG4000 transport 
and high TEER values and vice versa. In blank filters, 14.8% ± 2.1% (SEM) FITC-dextran 
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diffused after 75min apical-to-basolateral. Monolayers with the value ∆TEER > 900 Ω·cm2 
were defined as confluent, as the FITC-dextran or [14C] PEG4000 transport after two hours 
was below 2% respectively 0.15% (data not shown).  
After three days, cells formed a confluent monolayer on the membranes, where ∆TEER 
values of 900-3200 Ω·cm2 were achieved. After 7 days, cells were still confluent. When the 
values dropped down to 290 Ω·cm2, FITC-dextran was transported up to 11.1% ± 1.14% 
(SEM) after 120min from apical-to-basolateral (data not shown). Literature data have 
shown, that monolayers with ∆TEER values of 100 Ω·cm2 for HK-2 cell lines and 350 
Ω·cm2 for MDCK cell lines offer already sufficient tightness [128].  Time course of cell 
growth on transwell filters showed, that tightness of cells changes rapidly (300 Ω·cm2 
versus 1100 Ω·cm2 one day later).   
So far 900 Ω·cm2 was the lowest value where monolayers of  porcine proximal cells were 
still tight. Thus, the limit of tightness was deliberately set to 900 Ω·cm2 and to ensure 
absolute tightness, cells with ∆TEER values below 900 Ω·cm2, were not used in further 
experiments.  
 
2.4.3. Functional assays 
For functional assays the Transwell Costar 3460 system was used (Corning Incorporation, 
NY, USA). Cells were preincubated with the inhibitors for twenty minutes.  Both sides of 
the diffusion cells were filled with pre-warmed transport buffer (see below). The whole 
system was kept at constant temperature (37°C). At time t = 0, the substrate with or 
without inhibitor was added to the donor chamber. At defined time intervals, samples were 
drawn from the acceptor chamber and analysed. Uptake/transport assays were carried out 
in HBSS (Gibco) with 1mM MEM sodium pyruvate (Gibco), pH 7.4. Except for the dose-
dependent assays, radioactive substances were used at a concentration of 11100Bq per 
well (0.5ml in the apical and 1.5ml in the basolateral compartment). FITC-dextran 
(250µg/ml) or [14C] PEG4000 (11000Bq/well) was used for monitoring the monolayer 
integrity.  
For detection of radioactive substances, Packard 1900TR liquid scintillation counter was 
used. The samples were diluted in 3ml Insta-Gel Plus (Perkin-Elmer, Schwerzenbach, 
Switzerland). Detection of FITC-dextran and fluorescein was carried out with Perkin-Elmer  
HTS 7000 Bio Assay Reader with the following parameters: excitation at 485nm, emission 
535nm.  
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Table 2.1 – Primers designed for qualitative PCR, and primers/probes designed for quantitiative PCR 
(Taqman® assay) 
Data were analysed using apparent permeability coefficient Papp= ∆Q/∆t ? 1/(60 ? A ? C0) 
with the unit cm/s [129]. ∆Q/∆t is the permeability rate (mol/min), A the surface area of the 
membrane (cm2) and C0 is the initial concentration (mol/ml). Reading points were 5, 10, 
15, 20, 30, 60, 90 and 120 minutes.  
 
2.4.4. PCR 
Total RNA was isolated from confluent monolayers using the RNeasy Mini Kit (Qiagen, 
Hilden. Germany). RNA was quantified with a GeneQuant photometer (Pharmacia, 
Uppsala, Sweden). The purity of the RNA preparations was high, as demonstrated by the 
260 nm/280 nm ratio (range, 1.8-2.0). Its integrity was checked by ethidium bromide 
agarose gel electrophoresis. After DNAse I digestion (Invitrogen, Basel, Switzerland), 2 µg 
of total RNA was reverse transcribed by SuperScript II RT-Kit (Gibco) according to the 
manufacturer's protocol using random hexamers (Perkin-Elmer) as primers. The primer 
sequences and conditions for PCR are displayed in Table 2.1. Primers were synthesised 
by Invitrogen (Basel, Switzerland), probes by Eurogentec (Seraing, Belgium). PCR 
products were detected with agarose-gel electrophoresis using an agarose concentration 
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of 1.5% (w/V) (Invitrogen) and 0.5µg/ml ethidium bromide. The gel was run at 120V for 
50min. 
TaqMan analysis (quantitative RT-PCR) was carried out on a Gene Amp 5700 Sequence 
Detection System (Applied Biosystems, Rotkreuz, Switzerland). All samples were run in 
triplicates. A relative standard curve was generated by serial dilutions of cDNA. The 
dilution of the latter cDNA was expressed by the respective dilution value. Ct values of 
standards were plotted against the log of the respective dilution factors. Slope and y-
intercept of the standard curve line were then calculated by linear regression and used to 
calculate the input amount for unknown samples for respective genes. To standardise the 
amount of sample cDNA added to reaction the calculated amount of the gene of interest 
was divided by the calculated amount of the constitutively expressed glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) gene in the sample. These normalised amounts were 
then used to compare the relative amount of target in different samples.  
 
2.4.5. Sequencing of slc15a1 (PEPT1) and slc22a8 (OAT3) PCR products 
PCR products  were, after isolation with the Qiaquick Gel extraction kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s description and after quantification of DNA with 
Quant-iT™ Picogreen dsDNA Assay Kit (Molecular Probes, Leiden, The Netherlands), sent 
to Microsynth AG (Balgach, Switzerland) for sequencing. The received sequences were 
checked for homology with nucleotide-nucleotide blast at www.ncbi.nlm.nih.gov/BLAST/.  
2.4.6. Confocal microscopy 
For immunostaining, cells grown in Chamberslides® (Nalge Nunc International, Rochester, 
NY, USA) were used. Cells were washed 3 times with PBS and fixed for 20 minutes with 
4% (w/v) paraformaldehyde in PBS. After washing 3 times with PBS, tissues were 
permeabilised for 5 minutes with 0.5% (v/v) Triton X-100 in PBS. For immunostaining, cells 
were incubated for one hour at 37°C in a humid chamber with the primary antibody 
dissolved in PBS supplemented with 3% (w/v) BSA (bovine serum albumin). After washing 
twice with PBS, the fluorochrome conjugated secondary antibody dissolved in PBS 
supplemented with 3% (w/v) BSA was added for one hour at room temperature, in a dark 
chamber. Stained cells were then washed twice with PBS and mounted with FluorSave® 
(Calbiochem, San Diego, CA). Fluorescence stained cells were examined on a confocal 
Zeiss LSM 150 inverted laser scanning microscope (Carl Zeiss, Oberkochen, Germany). 
For fluorescein uptake, temperature control was used at 37°C, software: Carl Zeiss 
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LSM510 V3.2. All pictures except uptake of fluorescein are 400x magnified, excitation at 
the wavelength 488nm, fluorescein uptake: 100x magnification. The intensity of 
fluorescence was quantitatively determined with ImageJ 1.33u (National Institutes of 
Health, USA, http://rsb.info.nih.gov/ij/) by selecting 20 different spots in each image. Mean 
gray values were measured and analysed as described under statistical analysis.  
Primary antibodies used for these experiments were purchased at Alexis Biochemicals 
and used for ABCB1, ABCC1-5 staining: monoclonal antibody (Mab) to ABCB1 (human, 
JSB-1); mouse IgG1 Mab to ABCC1 (human; MRPm6); mouse IgG1 Mab to ABCC2 
(human; M2I-4), mouse IgG1 Mab to ABCC3 (human; M3II-9), rat IgG2a Mab to ABCC5 
(human; M5I-1). The primary antibodies for ABCB1, ABCC1, ABCC2 and ABCC3 were 
each diluted at a ratio of 1:50 and ABCC5 at a ratio of 1:25 with PBS and 3% FCS. For the 
staining of slc4a4 a polyclonal antibody was used from guinea pig serum (Chemicon 
International, Temecula, USA). The dilution rate used was 1:100. 
The following secondary fluorescent antibodies were used (Jackson Immuno Research): 
for ABCB1 and ABCC1-3 Cy2 AffiniPure rabbit Anti-Rat IgG (H+L), for ABCC5: Cy2 
AffiniPure Goat Anti Mouse IgG (H+L), for slc4a4 Cy2: AffiniPure Goat Anti Guinea Pig IgG 
(H+L), for double staining of ABCB1 and slc4a4 Cy3: AffiniPure Goat Anti Mouse IgG 
(H+L), and for slc4a4 the same secondary antibody as described above. 
 
2.4.7. Statistical analysis 
Statistical significance was investigated with t-test (two-tailed distribution with unequal 
variances). A probability of p<0.05 was defined as statistically significant. All transport and 
uptake studies were performed with primary cells obtained from two different isolations 
(exception: uptake with MTX and probenecid, see Table 2.2). Each isolation originated 
from at least two different pigs, as three or more pig kidneys have been used for one 
isolation procedure. Each transport or uptake assay was performed in triplicate. Results 
are expressed as the mean ± SEM.  
 
 
2.5. Results 
2.5.1. Expression of transporters at mRNA level 
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With RT-PCR (qualitative PCR), mRNA expression of slc5a2 (SGLT2), slc15a1 (PEPT1), 
slc22a8 (OAT3), slc4a4 (NBC1), slco1a2 (OATP-A) was shown, while slc22a1 (OCT1) and 
slc22a6 (OAT1) were only detected in freshly isolated proximal tubular cells (Fig. 2.2). 
Porcine GAPDH, slc5a2 and slc15a1 mRNA expression served as positive controls. Fig. 
2.2B shows that slc5a2 is expressed. With quantitative RT-PCR (Taqman® assay), abcc1 
(MRP1), abcc2 (MRP2) and abcb1 (P-gp) mRNA expression was revealed (Figure 2.3). 
Generally, an up-regulation of abcc1 and a down regulation of abcc2 during culture were 
noticed, while the level of abcb1 mRNA expression seems to remain constant.  
 
2.5.2. Sequencing 
Sequencing of slc15a1 (pPEPT1) band gave a 99% homology with the sus scrofa peptide 
transporter 1 (accession number: NM_214347 respectively AY180903).  
Figure 2.2 – (A): PCR of different transporters from freshly isolated primary proximal tubular cells: GAPDH 
(496bp), slc15a1 / PEPT1 (634bp), slc22a1 / OCT1 (464bp), slc22a6 / OAT1 (355bp), slc22a8 / OAT3 
(701bp), slc4a4 / NBC1 (241bp) and slco1a2 / OATPA (333bp). (B): PCR of slc5a2 / SGLT2 (494bp). The 
probes 1 and 2 are from pig kidney cortex while probes 3 and 4 are derived from isolated primary pig 
proximal tubular cells.   
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Slc22a8 (pOAT3) sequence gave a match of 99% with pOAT3 (accession Number: 
AJ587003 and NM_214455) (sequence data not shown).  
 
2.5.3. Functional assay 
The polar orientation of the cells growing on a surface was checked with confocal 
microscopy by double staining. The basolateral side of the cells was attached to the 
microscope slide. Abcb1 was shown to be predominantly expressed on the apical side of 
the cells (Fig. 2.4). The basolateral-to-apical abcb1 mediated transport and uptake of 
digoxin were inhibited by verapamil (Fig. 2.5A - B). Verapamil inhibited digoxin transport 
from basolateral-to-apical in a dose-dependent manner, whereas from apical-to-
basolateral transport of digoxin was enhanced with verapamil (not significant, data not 
shown).  
Uptake and transport of MTX seems to be complex as it is transported through different 
Figure 2.3 - Quantitative expression of abcb1 / P-gp (A), abcc1 / MRP1 (B) and abcc2 / MRP2 (C) normed 
to GAPDH. Culture 1 and 2 derived from two different isolations of different pigs. They were cultured as 
described in methods for 10-11 days. “Freshly isolated” means the proximal tubular cells were directly 
processed for RNA-isolation, DNA digestion and reverse transcription after isolation from pig kidneys.  
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subtypes of abcc1-6 (MRP1-6). All subtypes 
pump xenobiotics out of the cells, those at the 
basolateral side (abcc1, 3, 5, 6) are directed 
resulted also in an increased MTX uptake 
Table 2.2 - Uptake data after 2h. MTX 
(methotrexate) is used as model substrate for 
abcc1-6 (MRP1-6), whereas glycylsarcosine 
serves as a substrate for slc15a1/2 (PEPT1/2) 
and glucose for slc5a1/2 (SGLT1/2). 
into blood while those at the apical side 
(abcc2, 4) pump into urine.  At the apical s
(Fig. 2.6) the dose-dependent uptake of MTX, 
an abcc1-6 substrate, was enhanced by
specific abcc1-6 inhibitor MK571.
Basolateral inhibition of abcc1 by MK571 
ide 
 the 
 
(Table 2.2). These findings show a 
translocation of MTX both by abcc1 and 
abcc2. Indomethacin, a known abcc1 inhibitor, 
inhibited significantly MRP activity only at the 
basolateral side, where abcc1 is located 
transport of MTX from apical-to-basolateral 
ced uptake  and 
fect. 
(Table 2.2). Indomethacin tends to inhibit 
(Table 2.3) which also can be explained by 
selective inhibition of abcc1 at the basolateral 
side. This model, therefore, may allow a 
functional discrimination of the two subtypes 
abcc1, 2. MTX uptake in the cells was also 
inhibited by probenecid (Table 2.2). 
Fluorescein was used as model substrate for 
slc22a6-8 located at the basolateral side, 
transporting fluorescein from the blood into the 
cells. An inhibition of slc22a6-8 at the 
basolateral side means a redu
transport of organic anions. 
Transport of fluorescein from basolateral-to-
apical was inhibited by estrone sulfate, while PAH didn’t show any inhibitory ef
Probenecid showed a small and not significant inhibition (Table 2.3).  
Slc15a1/2 (PEPT1/2) is located at the apical side of renal proximal tubular cells and is 
Table 2.3 - Papp values after 1h. Fluore
model substrate for slc22a6-8 (OAT1
(methotrexate) for abcc1-6 (MRP1-
glycylsarcosine for slc15a1/2 (P
scein is a
-3
EPT1/2).
 
), MTX 
6) and 
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responsible for re-absorption of amino acids and oligopeptides. As a model compound, 
glycylsarcosine was used to demonstrate functional expression in our cells. Penicillin G 
(benzylpenicillin) was used as an inhibitor. Transport and uptake of glycylsarcosine could 
oximal tubular 
ells. In our cells glucose uptake could be inhibited by phlorizin (Table 2.2). 
 could 
e that slc22a8 (OAT3) expression was possibly higher than slc22a6 expression.   
stry. Abcc3 and 5 protein expression could not be shown by 
munostaining.  
 
be demonstrated in our cells and it was inhibited by penicillin (Table 2.3).  
Glucose is re-absorbed by slc5a1/2 (SGLT1/2) at the apical side of the pr
c
 
2.5.4. Uptake of fluorescein in viable cells 
With confocal microscopy it was possible to visualise the uptake of fluorescein into viable 
cells. In Fig. 2.7 the intensities are quantitatively plotted. The uptake was strongly reduced 
by addition of 200µM probenecid, 200µM estrone sulfate and 10mM penicillin (Fig. 2.7). 
With 100µM MTX and 200µM p-aminohippurate (PAH) the uptake of fluorescein was also 
inhibited (Fig. 2.7). However, the effect is not as strong as with probenecid. PAH was used 
as a slc22a6 (OAT1) inhibitor. An explanation for the lower inhibitory effect of PAH
b
 
2.5.5. Immunostaining 
In figure 2.8, staining of cells for slc4a4 (NBC1), abcb1 (P-gp), abcc (MRP) 1-3, 5 is 
shown. The presence of slc4a4, abcb1, abcc1 and abcc2 at protein level was shown by 
immunocytochemi
im
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Figure 2.5 – (A) Transport of 8.55nM digoxin with and 
without 100µM verapamil from basolateral-to-apical. (B) 
Uptake of digoxin at the basolateral side with and without 
100µM verapamil after 2h. 
Figure 2.6 - Uptake in cells at the apical side after 45 
min with different MTX concentrations. 
 
Figure 2.4  - Z-Stack of primary proximal 
tubular cells stained with ABCB1 and 
SLC4A4 starting from the apical side down 
to the basolateral side. CY3 staining (red) 
represents ABCB1 and CY2 staining 
(green) SLC4A4. 
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2.6. Discussion 
 
2.6.1. Expression of transporters on mRNA level 
The PCR bands of slc15a1 (pPEPT1) and slc22a8 (pOAT3) were located lower than they 
should be (634bp for pPEPT1 and 701 for pOAT3, Fig. 2.2). Therefore the PCR products 
of pPEPT1 and pOAT3 were sequenced and amplification of the right product was 
confirmed.   
The mRNA expression of porcine slc5a2 (SGLT2) and slc15a1 (PEPT1) was shown by 
RT-PCR and on a functional level. Slc5a2 and slc15a1 are restricted to proximal tubular 
cells only [111, 122]. Therefore, we conclude that the isolation procedure provided us with 
proximal tubular cells. In the kidney, slc5a2 and slc15a1 are restricted to the S1 segment, 
whereas slc5a1 (SGLT1) and slc15a2 (PEPT2) are restricted to the S3 segment [5, 111]. 
We did not screen our cells for porcine slc5a1, slc15a2, abcc3-6 and slc22a4/5 for mRNA 
expression since there is a lack of genetic information on these transporters in pigs.  
Slc4a4 (NBC1) is exclusively expressed at the basolateral side of the proximal tubular 
cells [37, 125]. Its specific staining provided further evidence for the proximal tubular origin 
of our cells. 
Since information about the porcine gene sequences of abcb1 (P-gp), abcc1 (MRP1), 
abcc2 (MRP2), slc15a1 (PEPT1), slc5a2 (SGLT2), slc22a1 (OCT1), slc22a6 (OAT1), 
slc22a8 (OAT3), slc4a4 (NBC1) and slco1a2 (OATP-A) was available, only mRNA 
expression of these genes was investigated in our cells. In freshly isolated cells mRNA 
expression of each of these transporters was demonstrated. Slc22a6 and slc22a1 mRNA 
expression was down-regulated in culture. A possibility to reach the „in vivo like“ 
expression of slc22a6 and slc22a1 is to induce slc22a6 gene expression with 
triiodothyronine [130], dexamethasone [131] or AST-120 [132] and slc22a1 gene 
expression with dexamethasone [133]. Another possibility is to use fresh isolated proximal 
tubular cells without culturing them for days. By this means a down regulation of 
transporters could be avoided. This should be investigated in a further series of 
experiments. 
Furthermore, abcb1, abcc1 and abcc2 mRNA expression was determined quantitatively 
showing a remarkable variability for abcc1 and abcc2, while abcb1 appeared to be 
constantly expressed in different isolations (Fig. 2.3). During culturing, abcc1 and abcc2 
were up- and down-regulated, respectively. 
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2.6.2. Protein expression 
The expression of slc4a4, abcb1, abcc1 
and abcc2 on protein level was shown 
by immunocytochemistry (Fig. 2.8A-D). 
However, abcc3 and abcc5 were not 
detected in our cells (Fig. 2.8E, F). This 
could be due to a lack of homology 
between human and porcine as we 
used antibodies against human ABCC3 
and ABCC5. To date, in pigs there is 
information available neither about 
abcc3 and abcc5 genes nor the 
respective protein structures.  
Abcb1 (P-gp) is located apically and 
slc4a4 (NBC1) basolaterally [37, 125]. 
With double-staining for abcb1 and slc4a4, the right spatial orientation of our cells growing 
on a surface could be confirmed. This gives us further evidence, that the cells are correctly 
orientated with the basolateral side on the microscope slide.  
 
Figure 2.7 - Intensity values from uptake of 1µM 
fluorescein after 30min, with 200µM probenecid, 
200µM estrone sulfate, 200µM PAH, 100µM MTX 
and 10mM penicillin.    
 
2.6.3. Tightness 
By TEER and FITC-dextran transport measurements as a negative control, we could 
ensure tightness of the monolayers for the transport and uptake assays. For the widely 
used MDCK cell line, which consists of distal tubular cells, transendothelial resistances 
were measured resulting in ∆TEER between 50-600 Ω·cm2 [128, 134-137]. Using dog 
urine extracts may increase ∆TEER in MDCK to values up to 800 Ω·cm2 [138]. According 
to Gallardo et al. [138], transepithelial resistance rises in vivo from the proximal tubular 
cells (5-8 Ω·cm2) to the distal cells (150-600 Ω·cm2) and along the collecting duct (860-
2000 Ω·cm2). In the LLC-PK1 cell line, which consists of proximal tubular cells, ∆TEER 
values range between 100-200 Ω·cm2 [134, 135, 139], while the interesting cell line HK-2 
(immortalised human proximal tubular cells) reaches a tightness of about 110 Ω·cm2 [128]. 
With the primary porcine proximal tubular cells ∆TEER values in general between 1500 
and 2500 Ω·cm2 can be obtained. With values below 900 Ω·cm2, transport assays were 
not possible: FITC-dextran was transported to a bigger extent indicating that the 
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monolayers were not confluent anymore. This cell culture model provides a much tighter 
monolayer than the other commonly used models. A higher transepithelial resistance 
means reduced paracellular transport (passive diffusion) through tight junctions. This may 
facilitate the discrimination of transport related from unspecific drug translocation. 
However, a correlation between in vivo and in vitro resistances in different parts of the 
kidney is difficult to establish. 
 
2.6.4. ABCB1 (P-gp) 
Expression of porcine abcb1 could be demonstrated on mRNA, protein and on a functional 
level. Abcb1 is located at the apical side (urine side, Fig. 2.1) and seems not to be down or 
up regulated during cultivation (Fig. 2.3A). Digoxin excretion was reduced with verapamil, 
a known abcb1 inhibitor (Fig. 2.5A). In the basolateral-to-apical experiment one would 
expect accumulation of digoxin in the cells. However, we found contrary results (Fig. 2.5B). 
Therefore, the mechanism of digoxin uptake into the cell is not completely solved. This 
may be explained by the inhibition of another not yet defined uptake mechanism of digoxin 
by verapamil at the basolateral side. One candidate of this uptake may by the human 
SLCO4C1 or a corresponding porcine transporter [87]. Its inhibition would than result in a 
decreased digoxin uptake.  
Figure 2.8 - Immunostaining of transporters, on the right bottom side corresponding negative control. 
Staining is positive for slc4a4/NBC1 (A), ABCB1/P-gp (B), ABCC1/MRP1 (C) and ABCC2/MRP2 (D).  
For ABCC3/MPR3 (E) and ABCC5/MRP5 (F) staining is negative. 
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2.6.5. ABCC1-6 (MRP1-6) 
Abcc1 and abcc2 mRNA could be shown in primary porcine proximal tubular cells even 
though abcc2 is down-regulated during culture as indicated by quantitative RT-PCR (Fig. 
2.3C). Abcc1-6 mediated transport is complex: Each result could be explained either by 
inhibition of abcc1 at the basolateral or of abcc2 at the apical side.  
Indomethacin inhibited abcc1 at the basolateral side, not at the apical side, where abcc2 is 
located (Table 2.2). Thus in this model indomethacin can be used as a selective abcc1 
inhibitor, as already described in [107, 140]. Nevertheless the system shows abcc1-6 
activity on both sides, as the uptake is enhanced with MK571 inhibition (Table 2.2), a 
selective abcc1-6 inhibitor [141, 142].  
Table 2.3 shows that apical-to-basolateral transport of MTX is inhibited with indomethacin 
which confirms that indomethacin inhibits selectively abcc1 at the basolateral side.  
 
2.6.6. Slc22a6/8 (OAT1/3) 
Slc22a6 and slc22a8 are expressed in freshly isolated cells, in cultured cells only slc22a8 
was detectable (Fig. 2.2). Fluorescein is a classical model substrate for slc22a6-8 [143]. 
They are located at the basolateral side and translocate organic anions into the cells in 
exchange for α-ketoglutarate (Fig. 2.1). As a general inhibitor of slc22a6-8 probenecid is 
used whereas estrone-sulfate inhibits slc22a8 selectively and PAH seems to be more 
selectively inhibiting slc22a6 [4]. PAH has a high affinity for porcine slc22a6 (Km =3.75µM) 
[144], whereas ES has a high affinity for rat slc22a8 (Km =2.3µM) [7]. Although no 
information on PAH affinity to porcine slc22a8 was found in the literature, a similar 
situation was described in rabbit proximal tubular cells where PAH is translocated by rabbit 
slc22a6 and not by rabbit slc22a8 and ES mainly by rabbit slc22a8 [145]. Also, in human 
SLC22A8 transfected Xenopus leaevis oocytes, ES has a higher affinity than PAH (Km 
3.1µM for ES and 87.2µM for PAH) [93]. In many species (from fish to mammals), the 
organic anion secretion system is expressed and functionally available [146]. Therefore, it 
is possible that substrate specificity and affinity remain comparable in all species. In the 
functional assay (Table 2.3), fluorescein transport could only be inhibited by ES and 
probenecid showed only a weak inhibition. This indicates the functional availability of 
porcine slc22a8. In freshly isolated cells, where slc22a6 and 8 are expressed, the 
inhibition with PAH is not as strong as with ES or probenecid (Fig. 2.7). A possible 
explanation could be that the porcine slc22a8 analogue has a higher affinity for fluorescein 
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or that functional activity of slc22a8 is higher than of porcine slc22a6. 
Interestingly, penicillin inhibits fluorescein uptake (Fig. 2.7), indicating excretion through 
slc22a6-8. MTX is not only transported through abcc1-6, but also by slc22a6-8 [6], as 
probenecid, an slc22a6-8 and abcc1-6 inhibitor [4], reduced MTX uptake at the basolateral 
side (Table 2.2). However, the transport of fluorescein, a slc22a6-8 substrate, could not be 
inhibited with 100µM MTX (Fig. 2.7). This may be explained by the fact that most data on 
transport of MTX through slc22a6-8 were generated in transfected models, where these 
transporters were over-expressed. Therefore, it is tempting to speculate that in this more 
complex and physiological model MTX translocation through slc22a6-8 seems to play only 
a minor role.  
 
2.6.7. Slc15a1/2 (PEPT1/2) 
These transporters translocate penicillin and other antibiotics, peptides and peptide-like 
substances. They are inwardly directed transporters located at the apical side of proximal 
tubular cells and play – under physiological conditions – an important role for the re-
absorption of amino acids and peptides from the urine.  
Glycylsarcosine is used as a model substrate for slc15a1/2. Whereas slc15a1 is mainly 
described as an intestinal transporter, slc15a2 is described as an renal transporter [122]. 
Although we could demonstrate slc15a1 mRNA expression (Fig. 2.2), genetic information 
on slc15a2 was to date not available. As both transporters slc15a1 and slc15a2 are 
directed inwardly into the cells at the apical side it is clear that the apical-to-basolateral 
transport of glycylsarcosine is reduced by penicillin (Table 2.3), an inhibitor of both 
transporters. On the other side, the basolateral-to-apical transport of glycylsarcosine was 
slightly enhanced by penicillin (not statistical significant, Table 2.3), as one would have 
expected.  
The uptake of glycylsarcosine at the apical side is inhibited (Table 2.2).  
 
2.6.8. Slc5a1/2 (SGLT1/2) 
Sodium-dependent glucose transporters are responsible for the re-absorption of glucose 
and other sugars. Both, slc5a1 and 2, are located at the apical side and transport sugar 
from the tubular lumen into the cell [111]. We could show their activity as glucose uptake 
at the apical membrane is significantly inhibited by phlorizin (Table 2.2), an inhibitor of 
these two transporters [111].  
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2.6.9. Transporters in other cell lines 
Parental HKC, HK-2 and MDCK were investigated for Na/HCO3 co-transporter (NBC), p-
glycoprotein (abcb1) and MRPs (abcc1-6) respectively [147-149]. A lot of information exist 
on transfected cell lines studying e.g. P-gp (abcb1), MRP2 (abcc2), OATP1B1 (sclo21a6), 
hOAT1 (SLC22A8) in MDCK [107, 108, 150], but also for LLC-PK1 [105, 106, 151] and 
HEK293 [109, 110, 118, 152] information is available. These interesting studies have 
investigated in an isolated manner the function of one to two transfected transporters in 
one cell line and seem to be useful to study, which drugs could potentially be translocated 
by the transfected transporters.  
In vivo, the situation is different, since many transporters are expressed concurrently. 
Transfecting and over-expressing of one or two drug transporters, lead to a changed in 
vitro system and ignored other possible active drug transporters. We are aware that in 
primary culture cells, the in vitro system is also changed by down- or up-regulation of drug 
transporters’ gene expression. Although we used the cells for a maximum of two weeks, 
such alteration in gene expression have been observed (see Fig. 2.3). Nevertheless, we 
could show preservation of functional expression of most of the investigated transporters 
in our unmodified system. Data on simultaneous functional expression of these drug 
transporters in parental proximal tubular cell lines, (such as LLC-PK1, HK2 and HEK293), 
are - as far as we know - to date not available. Despite these possible theoretical 
advantages of our primary cell culture model, we do not have experimental data to prove 
superiority over the commonly used cell lines. Therefore, a direct comparison of these 
models should be done using different model compounds and comparing this with in vivo 
data. However, these kind of experiments were beyond the scope of our capacity and 
facilities. 
 
2.6.10. Final conclusion 
Our model is based on a simple isolation of proximal tubular cells from readily available 
porcine kidneys. We could establish the functional validity of porcine primary proximal 
tubular cells for in vitro study. It might be an interesting tool to study in vitro drug 
elimination, tubular toxicity and drug interactions. Furthermore, it exhibits high 
transepithelial electrical resistance and thus monolayer tightness was ensured. In addition 
our model shows functional expression of the most important renal transporters for 
transport of xenobiotics simultaneously. Therefore, adverse effects resulting from drug-
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drug interactions might be investigated and/or predicted. On the other hand, it may allow 
simulating in vitro physiological processes more realistically.  
As already mentioned, primary cell cultures seem to have certain advantages compared to 
immortalised cells [103, 104]. 
Further studies are required, e.g. characterizing primary human proximal tubular cells in 
order to establish a correlation between human and pig transport activities in kidney. So 
far, the question concerning ligand specifities between human and pig transporters 
remains unanswered. However, pig kidney is apparently easy to obtain compared to 
human kidney and this species seems to be more closely related to human than rat, rabbit 
or mouse [10]. 
This in vitro model provides a basis to study the regulation of physiological transport 
processes and tubular toxicity. 
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3.1. Abstract 
Background: Breast cancer resistance protein (BCRP or ABCG2) is one of the multidrug 
resistance proteins which is currently under investigations. Its porcine homologue was 
found in brain capillary endothelial cells and therefore called brain multidrug resistance 
protein (BMDP). BCRP has shown to be responsible for chemotherapy resistances to 
various anti-cancer drugs, such as topotecan, irinotecan and mitoxantrone. To date, BCRP 
protein expression was found in several organs such as in lungs, pancreas, liver, placenta, 
intestine, urogenital system and kidney (tubular cells). The aim of this study was to 
investigate, if BMDP is functionally expressed in primary porcine proximal tubular cells 
(PPPTC). Furthermore, we wanted to investigate, if functional discrimination between 
BMDP and another multidrug resistant protein (P-gp, ABCB1) is possible. Finally, various 
drugs (antiepileptic agents, nonsteroidal anti-inflammatory drugs, proton pump inhibitors, 
caffeine, thalidomide, theophylline and dotatoc) were screened for an inhibitory effect on 
BMDP function.  
Methods: PPPTC were isolated from porcine kidneys. Expression of BMDP was measured 
at the mRNA level by quantitative RT-PCR. Protein expression of BCRP was verified with 
immunohistochemistry and Western blot analysis. Functional studies included uptake 
assays with the fluorescent BCRP substrate mitoxantrone and prazosin as inhibitor and 
various other drugs as well as the P-gp substrate digoxin with verapamil inhibitor.   
Results: In porcine proximal tubular cells, BMDP was found to be expressed at mRNA and 
protein level. Prazosin enhanced mitoxantrone uptake at the apical (urine) side, whereas 
verapamil did not show any inhibitory effect on BMDP. P-gp was functionally active, too. 
The discrimination of P-gp and BMDP activity was possible. Prazosin inhibited both, 
BMDP and P-gp function. From the tested drugs, only phenytoin inhibited BMDP. 
Conclusion: Functional expression of BMPD was shown in PPPTC. This transporter could 
potentially be involved in renal drug-drug interactions and excretion of drugs. Our study 
provides an in-vivo model based on primary porcine proximal tubular cell, which can now 
be used to test drug transport in the kidney with respect to BMDP and P-gp function.  
 
3.2. Introduction  
The breast cancer resistance protein (BCRP) is a member of the ABCG family and has a 
molecular weight of 72kDa [29, 153, 154], respectively around 70kDa [155] and authors in 
[156] even state a molecular weight of 65kDa. The porcine homologue of the human 
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BCRP was found in brain capillary endothelial cells and was named brain multidrug 
resistance protein (BMDP) with a sequence homology of 86% to the human BCRP [28].  
BCRP (ABCG2) belongs, similar to P-gp (ABCB1 alias P-glycoprotein), to the multidrug 
resistance proteins, which were first found over-expressed in tumour cells from patients 
with impaired chemotherapy [32]. Typical BCRP substrates are camptothecin derivatives 
(topotecan, irinotecan and its active metabolite SN-38, which are topoisomerase I 
inhibitors), flavopiridol, anthracyclines, the food carcinogen PhIP and the topoisomerase II 
inhibitor mitoxantrone, but not the typical P-gp substrates such as paclitaxel or vinca 
alkaloids [29, 32]. ABCG2 has been found in various normal human tissues such as 
intestine, pancreas, kidney cortex, hepatocytes and alveolar pneumocytes [30]. 
Interestingly, in human jejunum of healthy subjects the mRNA level of ABCG2 is about 
three times higher than that of P-gp [35]. Although a correlation between mRNA level and 
functional expression of the protein is difficult to establish, the latter finding indicates the 
importance of BCRP in multidrug resistance. In pig, BMDP expression was found in 
various tissues with highest expression in brain, kidney and lung [28].  
ABCG2 seem to have, similar to other multidrug resistance proteins, a protective function: 
Jonker et al. could show in [33] that Abcg2 knock-out mice developed severe to lethal 
phototoxic lesions upon ingestion of pheophorbide, a break-down product of chlorophyll, 
which occurs in plant-derived foods and food supplements. This protective function is also 
assumed for the brain, as BCRP is expressed at the blood-brain barrier [32]. 
Phenobarbital, phenytoin, ethosuximide, primidone, valproate, carbamazepine, 
clonazepam, and lamotrigine were investigated in a BCRP over-expressed MDCKII cell 
line, which is originally derived from distal tubular cells from dog, and these tested drugs 
showed no interactions with BCRP [157]. The authors conclude, that BCRP seems not to 
be responsible for therapy resistance of the tested antiepileptic drugs at the blood-brain 
barrier.  
As mentioned above, BCRP seems to be expressed in human kidney cortex. In mice, bcrp 
was found to be expressed in the brush border membrane of proximal tubules (apical 
side/urine side) [31]. Therefore, the aim of this study was to investigate if the porcine 
homologue BMDP is functionally expressed in primary porcine proximal tubular cells. This 
was investigated by quantitative RT-PCR, Western blot analysis and 
immunocytochemistry. For functional studies, the fluorescent BCRP substrate 
mitoxantrone and the inhibitor prazosin was used. Furthermore, we investigated, if we 
could discriminate P-gp and BCRP activity by using the P-gp substrate digoxin with 
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verapamil, prazosin and combination of both substances. Finally, we tested various 
antiepileptic drugs for BMDP interaction, most of them known to be excreted via the 
kidney: carbamazepine, carbamazepine-epoxide, gabapentin, lamotrigine, vigabatrine, 
phenytoin, felbamate and topiramate. Other substances were also tested which could be 
potentially excreted via kidney: acetylsalicylic acid, diclofenac, ibuprofen, indomethacin, 
fluvoxamine, clomipramine, imipramine, the proton-pump inhibitors ome-, lanso-, rabe- and 
pantoprazole, coffein, thalidomide, theophylline, yttrium- and gallium-dotatoc (dotatoc 
stands for [1,4,7,10-tetraazacyclododecane-N,N′N′′,N‴-tetraacetic-acid-D-Phe1-Tyr3]-
octreotide, a somatostatin analogue).   
 
3.3. Methods 
3.3.1. Materials 
MEM Eagle D-valine w/L-glutamine was purchased from Lucerna Chem AG (Luzern, 
Switzerland), Dulbecco’s MEM / Nut Mix F-12 (DMEM/F12), Fetal calf serum (FCS) and 
penicillin/streptomycin from Gibco Life Sciences (Basel, Switzerland), cell flask 75cm2 and 
24-well plates from BD (Franklin Lakes, USA), Fumitremorgin C from Alexis (Lausen, 
Switzerland). All other substances were purchased from Sigma/Fluka in highest quality.  
 
3.3.2. Cell Culture 
Porcine proximal tubular cells were isolated and seeded as described previously [158]. 
Cells were first seeded (1.5⋅106 cells in 75cm2 flask) in 50ml of 9.6g/1000ml MEM D-Val, 
10% FCS and 100U/ml penicillin/streptomycin and cultured for 5 days (after the first 48h 
media was changed every day). Then culturing was continued with DMEM/F12 with 10% 
FCS and 100U/ml penicillin/streptomycin until confluency was reached (about 3 days, 
media was changed every second day). The cells were incubated at 37°C in 95% air and 
5% CO2. For passaging, the monolayer was trypsinised with 10 ml (trypsin EDTA from 
Gibco) for 15 min. Then 10 ml of DMEM/F12 was added and centrifuged. After removing 
supernatant, the cell pellet was diluted in DMEM/F12. For uptake studies cells were 
transferred onto uncoated 24-well plates .  
 
3.3.3. RT-PCR for BMDP standards 
Total RNA was isolated from confluent monolayers using the RNeasy Mini Kit (Qiagen, 
Hilden. Germany). RNA was quantified with a Nanodrop Spectrophotometer (Witeg AG, 
Littau-Luzern, CH). The purity of the RNA preparations was high, as demonstrated by the 
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260nm/280nm ratio (range, 1.8 - 2.0). After DNAse I digestion (Invitrogen, Basel, 
Switzerland) 1µg of total RNA was reverse transcribed by SuperScript II RT-Kit (Gibco) 
according to the manufacturer's protocol using random hexamers (Perkin-Elmer) as 
primers. Gene amplification for generation of standards was performed by PCR in four 
25µl reaction units using AmpliTaq Gold DNA polymerase 1.25U (Applied Biosystems, 
Foster City, USA), dNTPs 200mM (Promega, Catalys AG, Wallisellen, Switzerland), 35ng 
cDNA (or DNA digested RNA for negative control), forward and reverse primers 0.4µM. 
The primer sequences and conditions used for BMDP (Accession no.: AJ420927) and for 
GAPDH (Accession no.: AF017079) are: BMDP forward 5′-
CTTCTCATGACCATCTCGTTTGTG-3′, BMDP reverse 5′-
CCCAAGCGGAGAGACTGATG-3′,  GAPDH forward 5`-CTTTGCCCCGCGATCTAA-3` 
and GAPDH reverse 5`-ACGATGCCGAAGTTGTCATG-3`. 
PCR was performed with Mastercycler personal (Eppendorf AG, Hamburg, Germany) 
using the following program: 1. step: 95°C over 10min, 2. step: 95°C over 30s, 3. step: 
annealing temperature.: 60°C for BMDP and 52°C for GAPDH, 4. step: 72°C over 1 min, 5. 
step: 72°C over 10 min, 6. step: cooling at 4°C. Steps 2 - 4 were repeated 44 respectively 
39 times. PCR products were detected with agarose-gel electrophoresis using an agarose 
concentration of 1.5% (w/v) (Invitrogen) and 0.5µg/ml ethidium bromide. The gel was run 
at 120V for 50min.  
 
3.3.4. Real-time Polymerase Chain Reaction (TaqMan® Assay) 
At the end of the culture period, medium was removed, total RNA was extracted and 
reverse transcribed as described above. TaqMan analysis was carried out on an Abi Prism 
7900 Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland). PCR 
conditions were 10min at 95°C followed by 40 cycles of 15s at 95 °C and 1min at 60°C. 
Each TaqMan reaction contained 10ng of cDNA in a total volume of 10µl. TaqMan 
Universal PCR Mastermix from Eurogentec (Geneva, Switzerland) was used. The 
concentrations of primers and probes were 900nM and 225nM, respectively. Primers and 
probes were designed according to the guidelines of Applied Biosystems with help of the 
Primer Express 2.0 software. Primers were synthesised by Invitrogen (Basel, Switzerland), 
probes by Eurogentec (Seraing, Belgium). All samples were run in triplicates. A standard 
curve was generated by serial dilutions of cDNA. The dilution of the latter cDNA was 
expressed by the respective dilution value. Ct (threshold cycle) values of standards were 
plotted against the log of the respective dilution factors. Slope and y-intercept of the 
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standard curve line were then calculated by linear regression and used to calculate the 
input amount for unknown samples for respective genes. To standardise the amount of 
sample cDNA added to the reaction the calculated amount of the gene of interest was 
divided by the calculated amount of the constitutively expressed glyceraldehydes-3-
phosphate dehydrogenase (GAPDH) gene in the sample. These normalised amounts were 
then used to compare the relative amount of target in different samples. All samples 
expressed GAPDH at same Ct values (20.18 ± 0.08). GLP-1R standard was generated 
using the respective Taqman primers without probe. PCR product was detected as 
described above on a 3% agarose gel.  
Following Taqman primers and probe have been used: GADPH probe 5'-
CGCCTGGTCACCAGGGCTGC-3', GAPDH forward 5'-GTTGAAGGTCGGAGTGAACG-3', 
GAPDH reverse 5'-CGACAATGTCCACTTTGCCA-3', BMDP probe 5’-
CGTCACAACAAACAATAC-3’, BMDP forward 5’-AACTTCTGCCCGGGACTCA-3, BMDP 
reverse 5’-GCCAGTACATATTGCGAAGCTACA-3.  
 
3.3.5. Sequencing of GAPDH and BMDP PCR products 
PCR was performed as described above. After detecting the bands on an agarose gel, 
they were cut out with a sterile scalpel. The PCR product was then extracted from the gel 
slice with the Qiaquick Gel extraction kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s description. After quantification of DNA with Quant-iT™ Picogreen dsDNA 
Assay Kit (Molecular Probes, Leiden, The Netherlands), the probes were sent to 
Microsynth AG (Balgach, Switzerland) for sequencing. Correct sequences were confirmed 
by nucleotide-nucleotide blast at www.ncbi.nlm.nih.gov/BLAST/ (data not shown).  
 
3.3.6. Confocal microscopy 
For immunostaining, cells grown in Chamberslides® (Nalge Nunc International, Rochester, 
NY, USA) were used. Cells were washed 3x with PBS and fixed for 20 minutes with 4% 
(w/v) paraformaldehyde in PBS. After washing 3x with PBS, tissues were permeabilised 
for 5min with 0.5% (v/v) Triton X-100 in PBS. For immunostaining, cells were incubated for 
one hour at 37°C in a humid chamber with the primary antibody dissolved in PBS 
supplemented with 3% (v/v) FCS (foetal calf serum). After washing three times with PBS, 
the fluorochrome conjugated secondary antibody dissolved in PBS supplemented with 3% 
FCS was added for one hour at room temperature, in a dark chamber. Stained cells were 
then washed three times with PBS and mounted with FluorSave® (Calbiochem, San 
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Diego, CA). Fluorescence stained cells were examined on a confocal Zeiss LSM 150 
inverted laser scanning microscope (Carl Zeiss, Oberkochen, Germany). The image was 
400x magnified. Fluorescence was detected with a wavelength for excitation at 488 nm 
and for emission between 505-550nm.  
Monoclonal antibody to human BCRP from mouse (BXP-21) used for these experiments 
was purchased from Alexis (Lausen, Switzerland). The dilution ratio was 1:50 in PBS with 
3% FCS. 
The following secondary fluorescent antibody was used (Jackson Immuno Research) and 
diluted in PBS with 3% FCS: CY2 AffiniPure goat anti mouse IgG (H+L) with a dilution rate 
of 1:50 and a final concentration of 5 µg/ml. 
3.3.7. Western blot analysis 
Proximal tubular cells were cultured in a 25cm2 cell culture flask from BD (Franklin Lakes, 
USA) until confluency was reached. Then proteins were extracted with 300µl protein 
extraction buffer (20mM Tris-HCl, 1% Igepal CA-630, 0.5mM sodium orthovanadate) 
including 1mM phenylmethylsulfonyl fluoride (Sigma-Aldrich, St. Louis, MO, USA) and 
protease inhibitor cocktail tablet, Complete Mini (Roche Diagnostics, Germany). The 
quantification of the protein content was performed with the BCA protein assay kit (Pierce 
Chemical, Rockford, IL, USA). Protein concentration was determined by measuring the 
absorbance at 562nm with Spectra MAX 250 Microplate Spectrophotometer (Molecular 
Devices Corporation, California, USA).  
For immunoblotting, lane A: 66µg, lane B: 35µg and lane C: 100µg (Fig. 3.2) of total 
protein extract was mixed with Laemmli sample buffer (Bio Rad Laboratories, Reinach, 
Switzerland) and transferred to the polyacrylamide gel. Gel electrophoresis was performed 
with a Mini Protean 3 Electrophoresis Cell (Bio Rad) applying 80V for 15min for the 
stacking gel (4% polyacrylamide) and 120V for 1hour for the separating gel (7.5% 
polyacrylamide). After electrophoresis, proteins were blotted to the nitrocellulose 
membrane (250mA for 2.5 hours) using a Mini Trans-Blot Cell (Bio Rad). Protein transfer 
was verified by Ponceau S staining. The membrane was blocked overnight at 4°C with 
PBS containing 5% milk powder and 0.05% Tween 20. After washing three times for 15 
minutes (0.05% Tween and 1% milk powder in PBS), the membrane was incubated for 2 
hours at 37°C with the primary, mouse anti-human antibody against BCRP, 5µg/ml (Alexis, 
Lausen, Switzerland) diluted 1:200 in PBS containing 0.05% Tween and 1% milk powder. 
After the first incubation, the membrane was washed three times for 15min and then 
incubated with the secondary, horseradish peroxidase-conjugated rabbit anti-mouse IgG 
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(Dako, Santa Barbara, CA) diluted 1:500. Secondary antibody incubation was performed 
for one hour at room temperature. Membranes were washed, and BCRP detection was 
performed with the enhanced chemiluminescence system (ECL-Detection-Kit, Amersham). 
The molecular weight was identified by using molecular weight Precision Plus Protein Dual 
Colour Standard (Bio Rad).  
 
3.3.8. Functional assays 
For functional assays, 24-well plates were used (BD). At time t = -30min, pre-warmed 
HBSS (Gibco) with 1mM MEM sodium pyruvate (Gibco), pH 7.4, with and without inhibitor 
was added to the well (apical side facing the solution). The whole system was kept at 
constant temperature (37°C). At time1 = 0min, media was changed, containing HBSS with 
1mM sodium pyruvate, mitoxantrone with and without inhibitor. After two hours, media was 
removed and cells were washed twice with HBSS/sodium pyruvate and incubated for 
30min with 5% Triton-X. Then supernatant was removed and transferred into a 96well 
plate (Perkin Elmer, Schwerzenbach, Switzerland). Fluorescence detection of 
mitoxantrone was performed with SpectraMax Gemini XS with Softmax Pro 3.1 from 
Molecular Devices (California, USA) at a excitation wavelength of 610nm, emission filter at 
685.  
 
3.3.9. Statistical analysis 
Statistical significance was investigated with t-test (two-tailed distribution with unequal 
variances). A probability of p<0.05 was defined as statistically significant. All transport 
studies were performed with primary cells obtained from two pigs. Each transport assay 
was performed in triplicate if not mentioned otherwise. Results are represented as the 
mean ± SEM. 
 
3.4. Results 
Expression of the brain multidrug resistance protein (BMDP) in porcine proximal tubular 
cells was detected by means of quantitative RT-PCR (Fig. 3.1). Interestingly, after 
incubation of cell culture (two weeks), the BMDP mRNA expression was down-regulated 
and, at the end of the third week, expression reached the initial expression level again.  
Protein expression was confirmed by Western blot analysis: A band of approximately 
72kDa, corresponding to the expected molecular mass for  the monomeric ABCG2, was 
detected (Fig. 3.2, lane A and B). As positive control, we used the human brain capillary 
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endothelial cell line BB19 (Fig. 3.2, lane 
C). The detected band at 140kDa 
represents the dimeric form of ABCG2. 
Further evidence for protein expression 
in proximal tubular cells was given by 
immunohistochemistry (Fig. 3.3). 
Functional activity of the breast cancer 
resistance protein (BCRP) respectively 
BMDP was shown by enhanced 
mitoxantrone uptake with the BCRP 
inhibitor prazosin (Fig. 3.4). No effect 
was detected with the P-gp inhibitor verapamil and the other BCRP inhibitor fumitremorgin 
C (FTC). The results in Fig. 3.5 show, as expected, an enhanced digoxin uptake with 
verapamil. However, the higher digoxin uptake with prazosin was somewhat surprising, 
which was even slightly higher in combination with verapamil (Fig. 3.5). The difference in 
inhibition between 100µM verapamil and 50µM prazosin was statistically significant 
(p<0.01), whereas the combination of prazosin and verapamil gave a slightly stronger 
Figure 3.1 - Quantitative PCR (Taqman): absolute 
quantification of BMDP mRNA in porcine proximal 
tubular cells at different days. 0d: freshly isolated 
cells without seeding them for culturing. Expression 
of mRNA was normalised to GAPDH. Data were 
pooled from two independent experiments, n=6.  
 
Figure 3.3 - Confocal microscopy: 
Immunostaining of BCRP with CY2 (green) and 
negative control. Size bar represents 50 µm 
Figure 3.2 - Western blot analysis of BCRP. 
Lane A and B: porcine proximal tubular cells, 
derived from two different isolations, lane C 
represents proteins from the human BB19 cell 
line. The monomeric form of BCRP has a 
molecular weight of around 70kDa.  
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inhibition of P-gp than prazosin alone, but this difference was statistically not significant 
(p=0.48). 
Screening of various antiepileptic agents for BCRP respectively BMDP inhibition showed 
only for phenytoin an effect (Fig. 3.6). Other substances, such as non-steroidal anti-
inflammatory drugs (NSAIDs), anti-depressants, and proton-pump inhibitors (PPIs), 
showed no significant inhibitory effect on BMPD, although a tendency was seen for 
ibuprofen, indomethacin and fluvoxamine (Fig. 3.7). Contrary to expectations, co-
incubation with diclofenac, caffeine, thalidomide, theophylline and gallium-dotatoc lead to a 
reduction of mitoxantrone concentration in the cells. This might be explained by inhibiton of 
mitoxantrone uptake through an unknown transport mechanism.  
  
 
 
 
 
Figure 3.4 - Mitoxantrone uptake at the apical side after 2h, cells were pre-incubated with the inhibitors 
for 30 minutes. MIT = mitoxantrone, Praz = prazosin, Verap = verapamil, FTC = fumitremorgin C,  
* p<0.05, ** p<0.01, *** p<0.001.  
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3.5. Discussion 
In mice and human, evidence exists 
for BCRP expression at the apical 
side of renal proximal tubules [31, 
33, 159, 160]. The objective of this 
study was to investigate, if  primary 
porcine proximal tubules do express 
the porcine homologue of BCRP, 
namely BMPD, at mRNA, protein 
level and if BMDP is functionally 
active.  
Expression at mRNA level was 
confirmed by quantitative RT-PCR, 
showing first a down-regulation of 
mRNA BMDP expression in the first 17 days during culturing and then reaching the initial 
level after 20 days (Fig. 3.1). If one can assume a correlation between mRNA and protein 
expression, it would have been optimal to perform functional assays either with fresh cells, 
which is difficult to perform without a confluent monolayer or cells which have been 
cultured around 20 days. Uptake experiments were performed between day 12-15, two 
experiments at day 24. At day 17, the effects were less pronounced. However, in cultured 
cells, protein expression was confirmed by Western blot analysis (Fig. 3.2) and by 
immunohistochemistry (Fig. 3.3). BCRP is known to be functional as a homodimer with 
disulfide bonds in between and a molecular weight of 130 respectively 140kDa. 
Accordingly, the BCRP monomer (“half transporter”) has a molecular weight of 65 
respectively 70kDa [156, 161]. Interestingly, the porcine proximal tubular cells seem to 
express the BMDP monomer, as the Western blot analysis was performed under non-
reducing conditions (Fig. 3.2 lane A and B). However, the BB19 cells seem to express 
mainly the dimer protein at 140kDa (Fig. 3.2 lane C). Intriguingly, [Arg482] ABCG2 is 
capable of translocating methotrexate even in presence of 10mM mercaptoethanol, a 
reducing agent breaking the disulfide bonds, indicating that ABCG2 may be to a certain 
extent functional as a monomer [162]. This latter finding seem to be the case in porcine 
proximal tubular cells, although it can not be excluded, that the half transporter BMDP 
spontaneously builds dimers in the membrane prior translocating substrates.      
 
Figure 3.5 - H3-Digoxin uptake at the apical side after 2h, 
cells were pre-incubated with the inhibitors verapamil 
(Verap), prazosin (Praz) and combined for 30 minutes. 
Cpm = counts per minute, ** p<0.01, *** p<0.001, n=6. 
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In order to test whether BMDP is functional available, the known BCRP substrate 
mitoxantrone was used in different concentrations with prazosin as inhibitor. In various cell 
lines, mitoxantrone was used in a concentration of 20µM [163]. Therefore, we used 50, 25 
and 10µM mitoxantrone for the first screening (Fig. 3.4). In literature, prazosin was used as 
an ABCG2 inhibitor with concentrations ranging from 1-50µM [156, 164-166]. We used 
prazosin at the highest concentration of 50µM. As mentioned in the beginning, in humans 
and in mice, BCRP is located at the apical side of the proximal tubules. Therefore, we 
assumed the same location in porcine tubules. All uptakes were performed in well plates, 
thus the apical side of these cells faces the solution, as already shown in [158]. The 
authors showed in [31], that in mice bcrp is involved in renal secretion of organic 
sulphates. Taking this into account, an inhibition of this transporter at the apical side would 
result in a reduced secretion of the substrates and accumulation in the tubule cells and in 
blood.  
Figure 3.6 - Mitoxantrone uptake at the apical side after 2h, cells were pre-incubated with 
antiepileptic agents for 30 minutes. Mitox = mitoxantrone, carba = carbamazepine, carba-epoxide 
= carbamazepine-10, 11-epoxide, * p<0.05, *** p<0.001, n=5. 
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Figure 3.7 - Mitoxantrone uptake at the apical side after 2h, cells were pre-incubated with various drugs 
for 30 minutes. Mitox = mitoxantrone, ASS = acetylsalicylic acid, Y = yttrium, Ga = gallium, * p<0.05,  
** p<0.01, n=4. 
 
In Fig. 3.4, it is shown, that mitoxantrone accumulated in porcine proximal tubular cells in 
the presence of prazosin, indicating the apical localisation of BMDP extruding substrates 
into lumen respectively into urine. Verapamil was given at a concentration of 100µM to 
exclude a P-gp mediated effect on mitoxantrone uptake, as verapamil is a known P-gp 
inhibitor, but no inhibitor of BCRP [160]. Fumitremorgin C (FTC), is reported to be likewise 
a BCRP inhibitor (Fig. 3.4) [167, 168].  One possible explanation could be, that FTC does 
not bind to the porcine BMDP. However, in other cell lines with human origin (BB19 and 
Caco) an inhibitory effect of FTC on BCRP could not be observed (data not shown). These 
cell lines were not over-expressing BCRP, another possible explanation for the lacking 
effect, that findings for FTC as a BCRP inhibitor was established mostly in over-expressing 
cells. Finally, the affinity of mitoxantrone to BMDP could be higher than that of FTC, thus 
preventing the expected interaction. 
The inhibitory effect of prazosin on BMDP seems to be maximal below 25µM  
mitoxantrone. Therefore, we performed further evaluation uptake assays with 20µM, 10µM 
mitoxantrone and 50µM prazosin (data not shown).  We have chosen 20µM mitoxantrone, 
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due to the better signal to noise ratio than with 10µM. Therefore, we decided to use 20µM 
mitoxantrone as final concentration for further experiments.  
 
As already shown in [158], P-gp is located at the apical side of porcine proximal tubules. 
Therefore, the principles of uptake and its inhibition are similar to BCRP: P-gp extrudes 
drugs out of the cell into urine. Inhibition of this transporter with verapamil resulted in an 
accumulation of digoxin in the cells, as shown in figure 3.5. Interestingly, prazosin was 
capable of inhibiting extrusion of digoxin much stronger than verapamil. It was shown, that 
digoxin is not translocated by BCRP although digoxin can inhibit BCRP [155]. Therefore, it 
can be excluded that the inhibitory effect of prazosin could be due to translocation of 
digoxin by BCRP. Furthermore, verapamil seems to be a relatively selective inhibitor for P-
gp compared to BCRP [160] and mitoxantrone uptake was not influenced by verapamil 
(Fig. 3.4). Prazosin again is not translocated by P-gp (as well as mitoxantrone) but 
prazosin could inhibit digoxin transport through P-gp as shown in Fig. 3.5 [165]. 
Interestingly, combination of verapamil and prazosin increased digoxin uptake slightly 
more than with prazosin alone, although this effect was not statistically significant. 
However, this latter finding is indicative that prazosin inhibits both P-gp and BCRP.   
 
In order to test a possible interaction of antiepileptic agents with BMDP in proximal tubular 
cells, we used concentrations of these drugs which are four-fold higher than the highest 
therapeutic blood concentrations. Although data already exists regarding BCRP and 
antiepileptic agents, we extended the “drug list” with some other not yet tested drugs which 
could be of potential relevance in the renal excretion [157]. Prazosin served as positive 
control for BCRP activity, whereas verapamil excluded a possible P-gp effect of 
mitoxantrone (Fig. 3.6). Only phenytoin showed an increased uptake of mitoxantrone 
indicating the possibility to inhibit BCRP/BMDP at least at high concentrations. With 
100µM phenytoin, no inhibitory effect could be shown (data not shown). We elucidated the 
possibility, that phenytoin is not only an inhibitor but also a substrate of BMDP. However, 
this hypothesis could not be confirmed with apical to basolateral transport (data not 
shown). Therefore, these results are in accordance with [157] and identify further 
antiepileptic drugs which are not inhibiting BCRP/BMDP (carbamazepine-10, 11-epoxide, 
gabapentin, vigabatrin, felbamate and topiramate). 
 
- 68 - 
In the next step, we tried to screen for further substances that might interact with 
BMDP/BCRP in proximal tubular cells (Fig. 3.7). So far, the tested NSAIDs, 
antidepressants, PPIs, caffeine, theophylline, thalidomide and both dotatocs showed no 
effect. Solely, ibuprofen, indomethacin and fluvoxamine showed a tendency to enhance 
mitoxantrone uptake, but this was not statistically significant. Interestingly, some 
substances were able to inhibit mitoxantrone uptake significantly (diclofenac, caffeine, 
thalidomide, theophylline and gallium-dotatoc). However, the mechanism of apical 
mitoxantrone uptake into proximal tubular cells is not yet completely resolved.  
 
In summary, our study could show for the first time expression of the porcine analogue of 
BCRP, the so called BMDP, in primary proximal tubular cells at mRNA, protein and 
functional level. In this porcine model, as described in [158], the concurrent expression of 
a further drug transporter enhances the possibility to reach a more realistic in vitro model 
as various drug transporters are expressed simultaneously. In order to compare the 
functional acitivity of the porcine transporter with the human BCRP, further investigations 
should be performed with the known BCRP substrates PhIP and prazosin. Then, possible 
interactions of drugs due to BMDP/BCRP in this in-vitro model must be compared with the 
in-vivo situation. Therefore clinical studies in human subjects are necessary. 
However, with this model it is now possible to screen various drugs regarding 
BCRP/BMDP and P-gp activity.  
 
Acknowledgments 
This work was supported by the Swiss national foundation. We express our gratitude for 
Ursula Behrens for the excellent technical assistance. 
 
 
 
 
 
 
 
 
 
- 69 - 
 
 
4. Glucagon-like peptide 1 receptor expression in primary porcine 
proximal tubular cells 
 
 
 
 
Schlatter P1., Beglinger C2., Drewe J. 1, Gutmann H1. 
 
 
 
1  Department of Clinical Pharmacology and Toxicology, University Hospital of Basel, 
Basel, Switzerland  
2  Division of Gastroenterology, University Hospital of Basel, Basel, Switzerland  
 
 
 
 
 
 
 
 
Submitted to: Regulatory Peptides 
 
- 70 - 
4.1. Abstract 
Background: GLP-1 is secreted into the circulation after food intake. The main biological 
effects of GLP-1 include stimulation of glucose dependent insulin secretion and induction 
of satiety feelings. Recently, it was demonstrated in rats and humans that GLP-1 can 
stimulate renal excretion of sodium. Based on these data, the existence of a renal GLP-1 
receptor (GLP-1R) was postulated. However, the exact localisation of the GLP-1R and the 
mechanism of this GLP-1 action have not yet been investigated.  
Methods: Primary porcine proximal tubular cells were isolated from porcine kidneys. 
Expression of GLP-1R was measured at the mRNA level by quantitative RT-PCR. Protein 
expression of GLP-1R was verified with immunocytochemistry, immunohistochemistry and 
Western blot analysis. Functional studies included transport assessments of sodium and 
glucose using three different GLP-1 concentrations (200pM, 2nM and 20nM), 200pM 
exendin-4 (GLP-1 analogue) and an inhibitor of the dipeptidylpeptidase IV (DPPIV) 
enzyme (P32/98 at 10µM). Finally, the expression of NHE3, the predominant Na+/H+ 
exchanger in proximal tubular cells, was also investigated. 
Results: GLP-1R, NHE3 and DPPIV were expressed at the mRNA level in porcine 
proximal tubular kidney cells. GLP-1R expression was confirmed at the protein level.  
Staining of human and pig kidney cortex revealed that GLP-1R was predominantly 
expressed in proximal tubular cells. Functional assays demonstrated an inhibition of 
sodium re-absorption with GLP-1 after three hours of incubation. Exendin-4 and GLP-1 in 
combination with P32/98 co-administration had no clear influence on glucose and sodium 
uptake and transport. 
Conclusion: GLP-1R is functionally expressed in porcine proximal tubular kidney cells. 
Addition of GLP-1 to these cells resulted in a reduced sodium re-absorption. GLP-1 had no 
effect on glucose re-absorption. We conclude that GLP-1 modulates sodium homeostasis 
in the kidney most likely through a direct action via its GLP-1R in proximal tubular cells. 
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4.2. Introduction 
Glucagon-like peptide 1 (GLP-1) is a hormone secreted from intestinal L-cells after food 
intake. The peptide is synthesised as a pre-proglucagon molecule that is subsequently 
metabolised to GLP-1 [169-171]. Different molecular forms of GLP-1 exist: GLP-1 7-36 
and 7-37 amide are bioactive forms [172], whereas GLP-1 9-36 and 9-37 amide are 
inactive metabolites [173].  In the following, we refer to the bioactive form GLP-1(7-36), if 
not stated otherwise. The GLP-1 receptor (GLP-1R) is a class B heptahelical G-protein-
coupled receptor with a molecular weight between 62-65kDa [174-180]. Upon GLP-1 
binding, adenylate cyclase is activated and intracellular cAMP is generated [180].  
 
The main effect of GLP-1 is stimulation of glucose-dependent insulin secretion from 
pancreatic β-cells thereby lowering blood glucose levels [181]. In vivo, GLP-1 is rapidly 
degraded by dipeptidylpeptidase IV (DPPIV) resulting in a short half-life of about two 
minutes [182]. Interestingly, DPPIV is highly expressed in renal proximal tubular cells and, 
therefore, can be used as a specific marker for these cells [183-186].  
 
Further effects of GLP-1 include induction of satiety and reduction of energy intake, both in 
healthy volunteers and in patients with diabetes type 2 [173, 187, 188].  
 
Furthermore, in rats and humans, exogenous administration of GLP-1 has a natriuretic 
effect [188-190]. In the kidney, about 60-70% of excreted sodium is re-absorbed in the 
proximal nephron, mainly by paracellular pathway and by a Na+/H+ exchanger (NHE3; 
SLC9A3) [191]. NHE3 exists in multimeric complexes with DPPIV at the apical side of the 
proximal tubular cells [57, 58], but the exact mechanism for this action has not been 
elucidated.   
 
The aim of the study was therefore 1) to screen human, pig kidney cortex and porcine 
proximal tubular cells for GLP-1R expression, 2) to characterise the effect of GLP-1 on 
porcine kidney cells on sodium and glucose re-absorption. Primary porcine proximal 
tubular cells were used to characterise GLP-1R expression by means of RT-PCR for the 
detection at mRNA level and immunoassays (Western-blot, immunohisto- and 
cytochemistry) for the detection at protein-level. For sodium transport measurements a 
fluorescence marker was used and for glucose transport measurements radioactive 
labelled 3H-Glucose.  
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4.3. Materials and Methods 
4.3.1. Materials 
MEM Eagle D-valine w/L-glutamine was purchased from Lucerna Chem AG (Luzern, 
Switzerland), Dulbecco’s MEM/Nut Mix F-12 (DMEM/F12), Fetal calf serum (FCS) and 
penicillin/streptomycin from Gibco Life Sciences (Basel, Switzerland), cell flask 75cm2 from 
BD (Franklin Lakes, USA), GLP-1 7-36 from Bachem (Bubendorf, Switzerland). P32/98 
was a kind gift from Dr. H.-U. Demuth from Probiodrug (Halle/Saale, Germany). All other 
substances were purchased from Sigma/Fluka in highest quality.  
 
4.3.2. Cell Culture 
Porcine proximal tubular cells were isolated and seeded as described previously [158]. 
Cells were first seeded (1.5⋅106 cells in 75cm2 flask) in 50ml of 9.6g/1000ml MEM D-Val, 
10% FCS and 100U/ml penicillin/streptomycin and cultured for 5 days (after the first 48h 
media was changed every day). Then culturing was continued with DMEM/F12 with 10% 
FCS and 100 U/ml penicillin/streptomycin until confluency was reached (about 3 days, 
media was changed every second day). The cells were incubated at 37°C in 95% air and 
5% CO2. For passaging, the monolayer was trypsinised with 10 ml (trypsin EDTA from 
Gibco) for 15 min. Then 10ml of DMEM/F12 was added and centrifuged. After removing 
supernatant the cell pellet was diluted in DMEM/F12. For transport studies cells were 
transferred on uncoated Transwell filter cell culture systems and for incubation studies on 
uncoated 6-well plates. In order to investigate the effect of glucose on the mRNA 
expression, cells were incubated, after passaging, in MEM D-Val, 10% FCS and 100U/ml 
penicillin/streptomycin containing 5mM Glucose and 15.6mM Glucose (corresponding 
glucose concentration of DMEM/F12) by adding from a 5M sterile filtered glucose solution.   
 
4.3.3. RT-PCR 
For quantitiative RT-PCR standards were generated for the genes NHE3 and DPPIV. 
Therefore, total RNA was isolated from confluent monolayers using the RNeasy Mini Kit 
(Qiagen, Hilden. Germany). RNA was quantified with a Nanodrop Spectrophotometer 
(Witeg AG, Littau-Luzern, CH). The purity of the RNA preparations was high, as  
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Gene 
RT-PCR Primers 
Accession no. Forward primer 
Reverse primer  
GAPDH AF017079 5`-AGATCATCAGCAATGCCTCCTG-3` 
5`-GAGCTTGACAAAGTGGTCGTTG-3` 
DPPIV AY198323 5’-TCCTACCAAATCGTTCCTCCG-3’ 
5’-GCTAAGGCACGTCACTTTTGTGTA-3’ 
slc9a3 AF123280 
 
5’-AAGTACGTGAAGGCCAACATCTC-3’ 
5’-TTCTCCTTGACCTTGTTCTCGTC-3’ 
Gene 
Taqman primers and 
probes 
 
Accession no. 
Forward primer  
Reverse primer  
Probe  
GAPDH AF017079 5’-GTTGAAGGTCGGAGTGAACG-3` 
5’-CGACAATGTCCACTTTGCCA-3` 
5’-CGCCTGGTCACCAGGGCTGC-3`  
GLP-1R CV871385 5`-TACTTCTGGCTGCTGGTGGAG-3` 
5`-ACCCCAGCCTATGCTCAGGTA-3` 
5`-ACCTGTACACGCTGCTGGCCCTGTC-3` 
DPPIV AY198323 5'-ATTTCCTCAGTGGCCCGG-3' 
5'-TCTGCAGGCCTAAATCTTCCA-3' 
5'-AACACATTGAAATCAGTACCACTGGCTGGG-3 
slc9a3 AF123280 
 
5`-GGACCCGCTCATCTGGAA-3` 
5`-ACCCGGTACACGGAGATAAAGAC-3` 
5`-AACACAGCCTTTGTGCTCCTGACGC-3` 
Table 4.1 - Sequences of porcine primers and probes 
demonstrated by the 260/280nm ratio (range, 1.8 - 2.0). After DNAse I digestion 
(Invitrogen, Basel, Switzerland) 1µg of total RNA was reverse transcribed by SuperScript II 
RT-Kit (Gibco) according to the manufacturer's protocol using random hexamers (Perkin-
Elmer) as primers. Gene amplification for generation of standards (except GLP-1R, see 
under Real Time PCR) was performed by PCR in four 25µl reaction units using AmpliTaq 
Gold DNA polymerase 1.25U (Applied Biosystems, Foster City, USA), dNTPs 200mM 
(Promega, Catalys AG, Wallisellen, Switzerland), 35ng cDNA (or DNA digested RNA for 
negative control), forward and reverse primers 0.4µM. The primer sequences, which were 
designed with Primer Express V 2.0 from Applied Biosystems, are displayed in table 4.1. 
Mg2+ concentration was 3mM for SLC9A3, DPPIV and GAPDH (glyceraldehyde 3-
phosphate dehydrogenase). 
 
PCR was performed with Mastercycler personal (Eppendorf AG, Hamburg, Germany) 
using the following program: 1. step: 95 °C over 10 min, 2. step: 95 °C over 30 s, 3. step: 
annealing temperature.: 55 °C, 4. step: 72 °C over 1 min, 5. step: 72 °C over 10 min, 6. 
step: cooling at 4 °C. Steps 2 - 4 were repeated 44 times. PCR products were detected 
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with agarose-gel electrophoresis using an agarose concentration of 1.5% (w/v) (Invitrogen) 
and 0.5µg/ml ethidium bromide. The gel was run at 120V for 50min.  
 
4.3.4. Real-time Polymerase Chain Reaction (TaqMan® Assay) 
At the end of the culture period, medium was removed, total RNA was extracted and 
reverse transcribed as described above. TaqMan analysis was carried out on an Abi Prism 
7900 Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland). PCR 
conditions were 10min at 95°C followed by 40 cycles of 15s at 95°C and 1min at 60°C. 
Each TaqMan reaction contained 10ng of cDNA in a total volume of 10µl. TaqMan 
Universal PCR Mastermix from Eurogentec (Geneva, Switzerland) was used. The 
concentrations of primers and probes were 900nM and 225nM, respectively. Primers and 
probes were designed according to the guidelines of Applied Biosystems with help of the 
Primer Express 2.0 software (Table 4.1). Primers were synthesised by Invitrogen (Basel, 
Switzerland), probes by Eurogentec (Seraing, Belgium). All samples were run in triplicates. 
A standard curve was generated by serial dilutions of cDNA. The dilution of the latter 
cDNA was expressed by the respective dilution value. Ct values of standards were plotted 
against the log of the respective dilution factors. Slope and y-intercept of the standard 
curve line were then calculated by linear regression and used to calculate the input 
amount for unknown samples for respective genes. To standardise the amount of sample 
cDNA added to the reaction the calculated amount of the gene of interest was divided by 
the calculated amount of the constitutively expressed glyceraldehydes-3-phosphate 
dehydrogenase (GAPDH) gene in the sample. These normalised amounts were then used 
to compare the relative amount of target in different samples. All samples expressed 
GAPDH at same CT values (20.18 ± 0.08). GLP-1R standard was generated using the 
respective Taqman primers without probe. PCR product was detected as described above 
on a 3% agarose gel.  
 
4.3.5. Sequencing of SLC9A3 (NHE3), DPPIV, GLP-1R and GAPDH PCR products 
PCR was performed as described above. After detecting the bands on an agarose gel, 
they were cut out with a sterile scalpel. The PCR product was then extracted from the gel 
slice with the Qiaquick Gel extraction kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s description. After quantification of DNA with Quant-iT™ Picogreen dsDNA 
Assay Kit (Molecular Probes, Leiden, The Netherlands), the probes were sent to 
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Microsynth AG (Balgach, Switzerland) for sequencing. Correct sequences were confirmed 
by nucleotide-nucleotide blast at www.ncbi.nlm.nih.gov/BLAST/ (data not shown). 
 
4.3.6. Confocal microscopy 
For immunostaining, cells grown in Chamberslides® (Nalge Nunc International, Rochester, 
NY, USA) were used. Cells were washed 3x with PBS and fixed for 20 minutes with 4% 
(w/v) paraformaldehyde in PBS. After washing three times with PBS, tissues were 
permeabilised for 5min with 0.5% (v/v) Triton X-100 in PBS. For immunostaining, cells 
were incubated for one hour at 37°C in a humid chamber with the primary antibody 
dissolved in PBS supplemented with 3% (v/v) FCS (foetal calf serum). After washing twice 
with PBS, the fluorochrome conjugated secondary antibody dissolved in PBS 
supplemented with 3% FCS with or without 60µg/ml propidium iodide was added for one 
hour at room temperature, in a dark chamber. Stained cells were then washed three times 
with PBS and mounted with FluorSave® (Calbiochem, San Diego, CA). Fluorescence 
stained cells were examined on a confocal Zeiss LSM 150 inverted laser scanning 
microscope (Carl Zeiss, Oberkochen, Germany). All pictures are 400x magnified. 
Fluorescence was detected with wavelengths for excitation at 488nm (CY2) and 543nm 
(propidium iodide), for emission between 505-550nm and 560-615nm, respectively.  
 
Polyclonal antibody to human GLP-1R from rabbit used for these experiments was 
purchased from Acris Antibodies (Hiddenhausen, Germany). Dilution ratio was 1:100 in 
PBS with 3% FCS. 
 
The following secondary fluorescent antibody was used (Jackson Immuno Research) and 
diluted in PBS with 3% FCS: GLP-1R CY2 AffiniPure Goat Anti Rabbit IgG (H+L) with a 
dilution rate of 1:25.  
4.3.7. Immunohistochemistry 
Formalin-fixed, paraffin embedded specimens were used for the immunohistochemical 
analysis by the avidin-biotin-peroxidase complex method (ABC Vectastain, Vector 
Laboratories, Burlingame, CA, USA).  
 
For experiments, 5 µm sections of kidney cortex were dewaxed and rehydrated in 
UltraClear (J.T. Baker, Deventer, Holland) for 30min, in 100, 96, 70% ethanol (each step 
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2-3min) and afterwards put into methanol with 0.3% H2O2 for 30min. After washing with 
PBS, protein kinase K 0.05% was applied for 5 min. As blocking agent horse serum was 
used for GLP-1R and BSA 1% in PBS for DPPIV and co-staining. Further steps were 
conducted according to manufacturer’s description. Negative controls for immunostaining 
were obtained by substituting the primary antibodies for PBS. Chromogenic detection was 
performed with 3,3-diaminobenzidine (DAB) for GLP-1R using horse radish peroxidase 
and fast red for DPPIV using alkaline phosphatase. Counterstaining was briefly performed 
with Mayer’s hematoxylin. The sections were dehydrated in ethanol 70%, 96%, 100% 
(each step 2-3 min) and finally in Ultra Clear. Mounting was performed with UltraKit 
Mounting Medium (J.T. Baker, Deventer, Holland). 
4.3.8. Western blot analysis 
Proximal tubular cells were cultured in a 25cm2 cell culture flask from BD (Franklin Lakes, 
USA) until confluency was reached. Then proteins were extracted with 300µl protein 
extraction buffer (20mM Tris-HCl, 1% Igepal CA-630, 0.5mM sodium orthovanadate) 
including 1mM phenylmethylsulfonyl fluoride (Sigma-Aldrich, St. Louis, MO, USA) and 
protease inhibitor cocktail tablet, Complete Mini (Roche Diagnostics, Germany). The 
quantification of the protein content was performed with the BCA protein assay kit (Pierce 
Chemical, Rockford, IL, USA). Protein concentration was determined by measuring the 
absorbance at 562nm with Spectra MAX 250 Microplate Spectrophotometer (Molecular 
Devices Corporation, California, USA). The same procedure was performed with a piece of 
human kidney cortex, received from the department of pathology of the university hospital 
in Basel.  
 
For immunoblotting, 100µg (Fig. 4.4) respectively 150µg (Fig. 4.5) of total protein extract 
was mixed with Laemmli sample buffer (Bio Rad Laboratories, Reinach, Switzerland) and 
transferred to the polyacrylamide gel. Gel electrophoresis was performed with a Mini 
Protean 3 Electrophoresis Cell (Bio Rad) applying 80V for 15min for the stacking gel (4% 
polyacrylamide) and 120V for 1h for the separating gel (7.5% respectively 10% 
polyacrylamide). After electrophoresis, proteins were blotted to the nitrocellulose 
membrane (250mA for 2.5 hours) using a Mini Trans-Blot Cell (Bio Rad). Protein transfer 
was verified by Ponceau S staining. The membrane was blocked overnight at 4°C with 
PBS containing 5% milk powder and 0.05% Tween 20. After washing three times for 15 
minutes (0.05% Tween and 1% milk powder in PBS), the membrane was incubated for 2 
hours at 37°C with the primary, rabbit anti-human antibody against GLP-1R, 1mg/ml (Acris 
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Antibodies, Hiddenhausen, Germany) diluted 1:500 in PBS containing 0.05% Tween and 
1% milk powder. After the first incubation the membrane was washed three times for 
15min and then incubated with the secondary, horseradish peroxidase-conjugated, donkey 
anti-rabbit IgG (Amersham, Buckinghamshire, UK) diluted 1:500. Secondary antibody 
incubation was performed for 1 hour at room temperature. Membranes were washed, and 
GLP-1R detection was performed with the enhanced chemiluminescence system (ECL-
Detection-Kit, Amersham). The molecular weight was identified by using molecular weight 
Precision Plus Protein Dual Colour Standard (Bio Rad).  
 
4.3.9. Functional assays 
For functional assays the Transwell Costar 3460 system was used (Corning Incorporation, 
NY, USA). For sodium transport, cells were preincubated with 200pM, 2nM, 20nM GLP-1, 
200pM Exendin-4, 10µM P32/98 and a combination of 200pM Exendin-4 or 200pM GLP-1 
with P32/98, for three hours.  Both sides of the diffusion cells were filled with pre-warmed 
buffer (see below). The whole system was kept at constant temperature (37 °C). At time 
t = 0, HBSS (Gibco) with 1mM MEM sodium pyruvate (Gibco), pH 7.4 with or without GLP-
1 was added to the donor chamber (apical). Acceptor media (basolateral) contained 
150mM choline chloride, 10mM Hepes, 2mM MgCl2, 2mM CaCl2 and 1µM cell impermeant 
Sodium Green (Invitrogen, Basel, Switzerland) in sodium free water (Sigma Aldrich, Basel, 
Switzerland).  At defined time intervals, samples were drawn from the acceptor chamber 
and analysed. [14C]PEG4000 (11000Bq/well) was used for monitoring the monolayer 
integrity (max. 0.2% of applied dose was transported).  
For glucose transport assays, pre-incubation was performed with 200pM, 2 and 20nM 
GLP-1 for three, 24, 48 and 72 hours. In both chambers of the Transwell Costar 3460 
HBSS was used with MEM sodium pyruvate as mentioned above. 3H-Glucose 
(11000Bq/well) was used in combination with 6.5µM glucose. Samples were drawn at 5, 
10, 15, 20, 30, 60, 90 and 120 minutes. To test monolayer integrity Fitc-dextran in a 
concentration of 250µg/ml was used (max. 0.8% of applied dose was transported). 
Glucose uptake was performed for three hours in 6-well plates with pre-incubation of  
GLP-1, exendin-4, P32/98 and its combinations as mentioned above. 
 
For detection of radioactive substances Packard 1900TR liquid scintillation counter was 
used. The samples were diluted in 3ml Insta-Gel Plus (Perkin-Elmer, Schwerzenbach, 
Switzerland). Detection of Sodium Green and Fitc-dextran was carried out with Perkin-
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Elmer HTS 7000 Bio Assay Reader with the following parameters: excitation at 485nm, 
emission 535nm.  
 
4.3.10. Cytotoxicity assay 
The effect of GLP-1, exendin-4 and P32/98 on cell viability was assessed using the 
sulforhodamine-B (SRB) colorimetric assay. Aliquots of primary porcine proximal tubular 
cells suspension were seeded onto 96-well plates. In order to test toxicity after three hours 
of incubation, cells were first incubated for 24 hours in blank medium and then treated with 
different concentrations of drugs in the culture medium.  
Toxicity was also tested for 96 hours changing the media with different concentrations of 
drugs every 24 hours. After incubation, cells were washed with medium and fixed with 5% 
trichloracetic acid in medium for one hour at 4°C. Subsequently cells were washed with 
water, air dried and stained with 0.4% SRB in 1% acetic acid for 15 minutes. Then the 
plate was again air dried, 10mM TRIS (pH=10.5) was applied for 5 minutes and absorption 
was measured at 540nm in Spectra Max 250 plate reader (Molecular Devices Corporation, 
CA, USA). Each condition was performed in five wells. 
 
4.3.11. Statistical analysis 
Statistical significance was investigated with t-test (two-tailed distribution with unequal 
variances). A probability of p<0.05 was defined as statistically significant. All transport 
studies were performed with primary cells obtained from two pigs. Each transport assay 
was performed in triplicate. Results are expressed as the mean ± SEM. 
 
4.4. Results 
Glucagon like peptide 1 receptor (GLP-1R), dipeptidyl-peptidase IV (DPPIV) and Na+/H+ 
exchanger isoform 3 (NHE3) mRNA expression was investigated by quantitative RT-PCR 
(Fig. 4.1). Glucose had no significant effect on the expression of these three genes (Fig. 
4.1).  
 
GLP-1R expression at the protein level was confirmed in primary porcine proximal tubular 
cells (Fig 4.2, 4.3D-F and 4.5) by immunocytochemistry, immunohistochemistry and 
Western blot analysis. In Fig. 4.4 homogenised kidney cortex slices from human (right 
lane) and pig (left lane) were used, whereas in Fig. 4.5 isolated porcine proximal tubular 
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cells were analysed. The acrylamid concentration of the gel in Fig. 4.4 is 7.5%, whereas in 
Fig. 4.5 the gel consists of 10% acrylamid.  
  
GLP-1R seems to be localised throughout the cell and a high staining was observed 
intracellular, near the nucleus (Fig. 4.2A). To assess the intracellular localisation of GLP-
1R expression in proximal tubular cells, a co-staining with propidium iodide was 
performed, as propidium iodide stains DNA respectively the nucleus (Fig. 4.2B, D). 
 
For immunohistochemistry and Western blot analysis, human kidney cortex was used as 
positive control (Fig. 4.3B and 4.4). DPPIV staining was performed in order to identify 
proximal tubular cells both in human and pig kidney cortex (Fig. 4.3A, D). In kidney cortex, 
GLP-1R seems to be expressed predominantly in proximal tubular cells, since staining of 
DPPIV (pink) and GLP-1R (brown) were overlapping (Fig. 4.3C, F). 
 
 
Figure 4.1 - Quantitative RT-PCR (Taqman): Absolute quantification of GLP-1R 
(Glucagon like peptide receptor), NHE3 (Na+/H+ exchanger isoform 3) and DPPIV 
(dipeptidyl-peptidase IV) mRNA in media containing two different glucose concentrations. 
Incubation was over 96 h. Expression of mRNA was normalized to GAPDH and 1µg RNA. 
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Figure 4.2 - Confocal microscopy: Immunostaining of GLP1R with CY2 (green) (A), costained with 
propidium iodide (red) (B), transmission picture (C) and superposed (D). Size bar represents 50 µm. 
Negative control is placed in the lower left corner.  
 
 
For sodium transport assays, cells were pre-incubated with 200pM, 2nM and 20nM GLP-1, 
200pM Exendin-4, 10µM P32/98 and combination of 200pM Exendin-4 or 200pM GLP-1 
with P32/98, for three hours. These conditions were chosen to have a comparison with a 
clinical study in healthy subjects and in insulin resistant obese men [188]. After 30, 60 and 
90min, apical-to-basolateral transport of sodium (corresponding to re-absorption) was  
significantly inhibited with 20nM GLP-1 (Fig. 4.6). Lower GLP-1 concentrations showed a 
Figure 4.3 - Immunocytochemistry: A-C human kidney cortex, D-F pig kidney cortex. A and D: staining for 
DPPIV (specific proximal tubular marker); B and E: staining for GLP-1R, C and F: double staining DPPIV 
and GLP-1R. Size bar represents 50µm. 
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slight, but statistically not significant inhibition. 10µM P32/98 alone and in combination with 
200pM Exendin-4 or 200pM GLP-1 showed no inhibition (data not shown). 
Glucose transport assays from apical to basolateral were performed with 200pM, 2 and 
20nM GLP-1 without any differences (data not shown). Glucose uptake with GLP-1, 
exendin-4, P32/98 and its combinations showed inconclusive results (data not shown). 
 
All drugs used did not show any toxicity after three or ninety-six hours at the mentioned 
concentrations (data not shown).  
 
4.5. Discussion 
Renal effects of GLP-1 have been documented in vivo, both in healthy subjects and in 
obese persons [188]. The findings were supported by animal data in anaesthetised rats. 
When the animals received GLP-1 infusion, a remarkable 13-fold increase of sodium 
excretion was observed [189]. The authors postulated that the inhibitory effect of GLP-1 on 
sodium re-absorption was a direct action on the proximal tubules and not due to a change 
in renal hemodynamics.  
 
In vitro investigations have confirmed the tissue distribution of GLP-1R in rat and mouse at 
mRNA level [192-196]. With one exception [195], GLP-1R expression was always found in 
the kidney.  
 
Though information is available on the expression of GLP-1R in the human kidney at 
mRNA level [197], the intrarenal distribution of GLP-1R has not clearly been defined yet 
nor has it been investigated whether in particular proximal tubular cells express GLP-1R. 
Therefore, it was the objective of this study, to confirm renal expression of GLP-1R and to 
evaluate, whether this expression was confined to proximal tubular cells in kidney cortex. 
Furthermore, we tried to show the cellular distribution and the regulation of expression of 
GLP-1R as well as the effect of GLP-1 administration on proximal tubular cell sodium re-
absorption. 
 
In the first experiments, GLP-1R mRNA expression was shown in renal tissue by RT-PCR. 
In previous studies we have observed GLP-1 effects on renal sodium re-absorption in 
obese subjects with impaired glucose tolerance. In the following experiments, we therefore 
investigated the effect of glucose on GLP-1R mRNA expression. The expression levels of 
- 82 - 
GLP-1R, DPPIV and NHE3 were not dependent on glucose concentrations (5.0 and 
15.6mM) (Fig. 4.1). However, using a high glucose concentration (22mM) in a mouse 
pancreatic beta cell line (MIN6), an up-regulation of GLP-1R expression was observed 
[195]. We can only speculate on the physiological importance of this latter finding. 
Furthermore, the lack of induction of GLP-1R expression at mRNA level in primary porcine 
proximal tubules may be explained by the lower (more clinically relevant) glucose 
concentrations used in this study or by species differences (pigs versus mice). In addition, 
we have shown that GLP-1, exendin-4 and P32/98 did not influence the mRNA expression 
of GLP-1R, DPPIV, NHE3, sodium- dependent glucose transporter slc5a1, slc5a2 (SGLT1, 
2) after incubation over 96 hours (data not shown).  
 
GLP-1R expression was confirmed on the protein level using immunohistochemistry, 
immunocytochemistry and Western blot analysis (Fig. 4.2-4.5). This analysis showed that 
GLP-1R protein was found in the kidney cortex, predominantly in proximal tubular cells. 
This was proven by co-staining with DPPIV, which is exclusively expressed in proximal 
Figure 4.5 - Western blot of three different 
samples of primary porcine proximal 
tubular cells from two different isolations, 
each isolation derived from kidneys of two 
pigs. Gel run on a 10% polyacrylamide gel.  
 
Figure 4.4 - Western blot of GLP-1R left lane: 
pig kidney cortex, right lane: human kidney 
cortex run on a 7.5% polyacrylamide gel. 
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tubular cells (Fig. 4.3). Interestingly, Fig. 4.3E shows a distribution of GLP-1R throughout 
the cells, although we would have expected a concentration of GLP-1R protein expression 
at the apical side, as GLP-1 influenced sodium transport there. Authors in [177] deliver an 
possible explanation for the distribution of GLP-1R in the cells: The receptor is internalised 
upon GLP-1 binding. Afterwards endosomal membrane fractions was found to be enriched 
with GLP-1R. Furthermore, the authors could show a cycling of the receptor between 
endosomal compartments and plasma membrane. However, our preparation for 
immunocytochemistry was performed without GLP-1 application. Additional experiments 
are required in order to clarify the intracellular protein distribution and function. 
 
For our functional experiments, higher GLP-1 concentrations were applied (significantly 
higher than those observed physiologically). These concentrations were chosen, since 
GLP-1 is very rapidly (half-life of 2min) degraded in vivo by DPPIV [182]. DPPIV 
represents the major renal catabolic pathway for GLP-1 [198]. Therefore, in order to 
measure the direct effects of GLP-1 on primary porcine proximal tubular cells, either 
supra-physiological concentrations of GLP-1 need to be applied and/or DPPIV has to be 
blocked by specific inhibitors (such as P32/98). In patients with type 2 diabetes, 
supraphysiological GLP-1 serum concentrations of 50 to 120pM have been shown to lower 
glucose plasma concentrations. These concentrations are 3-5 fold higher than those 
reached after a meal or oral glucose intake [173]. 
 
Since our in vitro model consists of proximal tubular cells and DPPIV is abundantly 
expressed at the cell surface (apical side) in proximal tubular cells (and used as a marker 
for these cells) [183-186], a high activity of DPPIV is expected.  
 
We therefore used high GLP-1 concentrations of 200pM to 20nM. The experiments of 
GLP-1 were compared with exendin-4 (200pM), a GLP-1 receptor agonist with a prolonged 
half-life of 2-4 hours [173], which was shown to be active in concentrations above 12pM 
[199]. To study inhibition of DPPIV, P32/98, a specific blocker of this enzyme was used at 
a concentration of 10µM, a concentration, which was effective in opossum kidney proximal 
tubule cells [58].  
 
With 20nM GLP-1, we could show a significant inhibition of sodium re-absorption without 
using a DPPIV inhibitor (Fig. 4.6). Lower concentrations were ineffective although there 
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was a trend towards inhibition. However, 200pM GLP-1 and 10µM P32/98 given alone and 
in combination also failed to show a significant inhibition of sodium re-absorption (data not 
shown, n=6). A possible explanation of the latter finding could be that P32/98 does not 
bind to porcine DPPIV. Furthermore, in opossum kidney cells, even a complete inhibition 
of DPPIV with P32/98 resulted in only a 45% inhibiton of NHE3 [58]. It is possible that the 
expression pattern of the five existing Na+/H+ exchanger isoforms differs somewhat 
between pig and opossum that an partial inhibition of NHE3 isn’t sufficient enough to 
influence the overall sodium re-aborption in porcine proximal tubular cells.  
 
 
When we used the DPPIV resistant GLP-1 analog exendin-4, a concentration of 200 pM 
with and without additional administration of 10µM P32/98 had also no effect on sodium re-
absorption (data not shown, n=6). This lack of effect is somewhat surprising. Although 
exendin-4 has only a 53% amino acid sequence homology with human GLP-1 [200], 
exendin-4 binds in vitro (rat and human) with similar affinity to the pancreatic GLP-1 
Figure 4.6 - Sodium transport after 3h incubation from apical to basolateral (n=3), representative for three 
independent experiments. Sodium is measured with sodium green indicator (tetramethylammonium salt) 
by fluorescence. 
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receptor as GLP-1 [201]. On the other hand, exendin-4 does not mimic all GLP-1 effects 
such as suppressing gastric acid secretion or activating hepatic vagal afferent nerves 
[202]. Recent findings even indicate that exendin-4 exerts additional effects, which are not 
mediated by GLP-1 receptor activation [201]. Further alternative explanations may be 1) a 
GLP-1 metabolite is necessary for this effects or 2) exendin-4 does not bind to the porcine 
GLP-1 receptor.  
 
Inhibition of sodium transport from apical-to-basolateral (urine to blood) indicates 
enhanced secretion of sodium from blood to urine compartment. This fact corresponds 
with a clinical study: a significantly increased natriuresis was seen in men receiving 
intravenous GLP-1 for three hours [188]. Since the clinical data demonstrated, that plasma 
glucose levels were lowered by GLP-1 infusion, we also checked a possible effect of GLP-
1 on glucose re-absorption in porcine proximal tubular cells. However, glucose transport 
was not affected with 200pM, 2 and 20nM GLP-1. Uptake with GLP-1, exendin-4, P32/98 
and its combinations showed inconclusive results (data not shown). 
 
The mechanism of the observed inhibition of sodium re-absorption is still not clear. A 
possible explanation could be a conformational change of the NHE3-DPPIV complex by 
GLP-1, resulting in a reduced transport activity of NHE3. This transporter is critical for the 
proximal tubular sodium re-absorption [191]. On the other hand, it is not yet resolved, 
which isoform of NHE is responsible in our cell line model, as mRNA expression of NHE3 
was very low. Therefore, it may be speculated that such a conformational effect of GLP1 
on the NHE3-DPPV complex would be independent of GLP-1R activation. Another 
possibility could be that the GLP-1 mediated increase in intracellular cAMP concentrations 
could influence the activity of the different NHE isoforms in the kidney. Indirect evidence 
for this explanation comes from experiments with intestinal cells, which showed that an 
intracellular rise of cGMP inhibits sodium absorption notably through inhibition of NHE 
transporters [203].  
Finally, further investigations are required in order to elucidate 1. GLP-1R expression in 
other parts of the kidney and to which part it would contribute to physiology, 2. the effect of 
GLP-1 on intracellular cAMP production.  
 
In conclusion, we have found further evidence for a direct renal action of GLP-1 in a 
porcine primary cell culture model of proximal tubules. These in vitro findings are in 
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agreement with findings in animals, and clinical observations in healthy volunteers and 
patients. Although the cellular mechanisms of this GLP-1 action remain unclear, this work 
demonstrates that GLP-1 has a direct effect on sodium re-absorption in primary cultures of 
porcine proximal tubular cells. 
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5. Conclusion and outlook 
 
Development of one successful pharmaceutical lasts about 10 years and costs, according 
to pharmaceutical companies around 800-1000 million US-Dollars (includes also costs for 
unsuccessful projects) [204]. Therefore it is of great interest to filter potentially “dangerous” 
pharmaceuticals in an early stage of drug discovery and development in order to prevent 
the costly and awkward situation of withdrawing a drug from market after 10 years of 
development due to a drug-drug interaction. Various “filtering” systems do exist. One of 
them is to use predictive in-vitro models, preferentially with high throughput screening 
capacities. In addition, an advantageous validated system can reduce costly and 
unnecessary animal tests.   
 
In this thesis, we provide a new validated in-vitro model, which expresses various drug 
transporters functionally and simultaneously. Many drugs are often transported not only by 
one specific transporter (chapter 2.2). Therefore, this in-vitro model can now be used to 
test substances for tubular toxicity or to screen for possible drug-drug interactions in 
proximal tubules with the advantage to have various drug transporters available in one 
system without altering it by e.g. transfection. We are aware, that the definitive 
confirmation, whether this in-vitro model has more advantages compared to other 
established cell lines (LLC-PK1, HK2, HEK293, etc.), is yet to be performed. Even if the 
mentioned benefits are more theoretical, though plausible, we believe to provide an 
interesting tool for further studies. One of them would be to compare porcine with human 
transporter properties either by isolating these cells from human kidney or to confirm future 
findings in the porcine model with human clinical studies. Furthermore, evidence has to be 
supplied for high throughput screening capacities. Under certain conditions, such as using 
fluorescence markers (e.g. mitoxantrone) in 96 wells for uptake measurements, high 
throughput screening could be possible.  
 
In addition, this system expresses genes, which are currently of great interest in diabetes 
research regarding GLP-1, its analogues and inhibitors of the degrading enzyme DPPIV. 
Therefore, in this part of the kidney, it is now possible to investigate the effect of these 
substances, which will be soon launched onto market. 
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